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Mitochondria are known as the powerhouse of the cells. However, in recent years, it has become 
increasingly evident that mitochondria are involved in several signaling pathways. Lysosomes are 
membrane-bound organelles that receive and degrade macromolecules from the secretory, 
endocytic and autophagy pathways. Our lab has recently reported that mitochondrial respiratory 
chain deficiency inhibits lysosomal hydrolysis and that lysosomal lipid storage diseases are 
characterized by the repression of mitochondrial biogenesis; thereby showing interdependence 
between these organelles. However, little is known about the connection between the 
dysfunction of these organelles and lipid metabolism. 
Here, we aimed to elucidate if the dysfunction in mitochondria or lysosomes yields any 
consequences on lipid metabolism, more specifically cholesterol biosynthesis, and to describe 
the underlying mechanism. We have employed cell lines with defects in each of these organelles 
and measured the effects on gene expression by RNA sequencing (RNA-Seq), followed by 
comprehensive multi-dimensional transcriptomics analysis, as well as by quantitative real-time 
PCR. Interestingly, changes in the expression of genes of the cholesterol synthesis pathway were 
among the significant consequences of both the mitochondrial and the lysosomal perturbations, 
but with opposite trends. While mitochondrial dysfunction results in the downregulation of the 
cholesterol biosynthesis, lysosomal dysfunction leads to its activation.  
Analysis of the cholesterol content showed a significant decrease of unesterified (free) 
cholesterol level in cells with mitochondrial dysfunction. On the other hand, free cholesterol level 
was increased in the cells with lysosomal dysfunction. Mitochondrial cholesterol content was 
increased only in the cells with mitochondrial dysfunction. 
To further investigate the origin of the opposite trends of cholesterol biosynthesis resulting from 
organelle dysfunction, we measured the activity of SREBP1, an established regulator of the 
cholesterol biosynthesis. We found a decrease in the SREBP1 activity in cells with mitochondrial 
dysfunction and its increase in the case of lysosomal dysfunction. The crucial role of AMPK in the 
regulation of the cholesterol biosynthesis pathway is evidenced by the changes in AMPK activity 
in the cells with organelle dysfunctions: while in the case of mitochondrial dysfunction AMPK 
showed increased activity, the trend was opposite in the cells with lysosomal dysfunction. 
Importantly, based on our results, the effect of organellar dysfunction on cholesterol biosynthesis 
depends on AMPK activity. 
This work contributes to the understanding of the underlying mechanisms of pathologies 
associated with organelle dysfunction, such as lysosomal storage diseases or mitochondrial 
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Cells are the fundamental units of life, from which we must look for answers to the questions of 
what life is and how it works. A typical structure of all cells is that each of them is enclosed by a 
plasma membrane. This membrane is essential for the cell because it acts as a selective barrier 
allowing the cell to concentrate nutrients obtained from the environment and keep within its 
interior the newly synthesized macromolecules while excreting its waste products. As such, the 
cell acquires its integrity as a coordinated chemical system thanks to the plasma membrane. 
Biological membranes consist of a bilayer formed by amphiphilic molecules, mostly lipid 
molecules, and proteins. 
Today, cells are grouped into three major divisions or domains: bacteria, archaea, and eukaryotes 
(Alberts, 2014). Whereas the cytological properties of bacteria and archaea are relatively simple, 
eukaryotes are characterized by a high degree of cellular complexity (Spang et al., 2015). Bacteria 
and archaea are unicellular entities, formed by prokaryotic cells. These cells have in common a 
lack of membrane-bound organelles or other internal membrane-bound structure. 
Eukaryotic cells, by definition, have an internal compartment called nucleus that divides the DNA 
from the cytoplasm. The double-layer membrane that surrounds the nucleus is denominated 
nuclear envelope. Another critical component of eukaryotic cells is the presence of organelles, 
intracellular membrane-bound structures inside the cell usually specialized for a particular 
function (Mullock and Luzio, 1976). 
The mitochondrion is an exceptionally complex organelle. Due to its prokaryotic origin almost 1.5 
billion years ago (Dyall, 2004), this organelle has two membranes, inner and outer mitochondria 
membrane, and its small genome. Although the mitochondria are well known to be essential for 
bioenergetics, the complexity of mitochondrial metabolism has been reported in emerging 
research, associating it to diverse functions (Spinelli and Haigis, 2018). 
Lysosomes, or vacuoles as they are referred to as in fungi and plants, are organelles which 
function as the significant degradative compartment in the cell. Lysosomal pH is maintained 
between 4.6 – 5.0 actively and mainly by a proton-pumping vacuolar ATPase (vATPase) although 
there are more transporters that contribute to lowering the pH, such as the SLC36 family (amino 
acid transporter) (Thwaites and Anderson, 2011) and CIC-7 (chloride antiporter) (Scott and 
Gruenberg, 2011). The low pH allows the acidic hydrolases to be able to degrade the 
macromolecules delivered to the lysosome (Lübke et al., 2009). They are associated with 
different degrative pathways, such as endocytosis where lysosomes are the terminal organelle 
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and autophagy, the process in which the intracellular material is isolated and digested (Luzio et 
al., 2007) (Olson and Joyce, 2015). 
Lipids play an essential role in different cellular processes and are one of the primary class of 
biological membranes. Different thousands of lipids are synthesized in mammalian cells, as well 
as hundreds of proteins to synthesize, metabolize, transport them (Muro et al., 2014). However, 
less is known about lipids than any other different kind of molecules such as proteins. Even today 
when lipids can be used in laboratories for signaling, cell structure, and other functions the 
knowledge about their function in lipid droplets, lipoproteins, and biological membranes is still 
rudimentary (Merrill, 2013). This project focuses on changes in the cholesterol synthesis as a 




1.2 Mitochondrial biology 
The most common phrase that precedes an introduction to mitochondria is: “mitochondria, the 
organelles that act as cellular powerhouses”(de Bock and Thorne, 2016). However, nowadays, it 
is accepted that mitochondria are multifaceted organelles involved in several essential processes 
for the cell.  
Mitochondria have a role in critical in the cell being part of processes such as autophagy, cell 
proliferation, differentiation, cellular immunity, and apoptosis (Nunnari and Suomalainen, 2012; 
Raimundo, 2014). Several diseases have been associated with mitochondrial dysfunction. Genetic 
disorders, characterized by defects in the mitochondrial system, are a group of pathologies 
denominated mitochondrial diseases. These diseases are mainly caused by mutations in genes 
that encode proteins involved in the function or structure of the mitochondria. The mutations 
can be present in genes encoded in the mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) 
(Gorman et al., 2016). Mitochondrial diseases present a different phenotype in patients, affecting 
several different organs, and generating a multisystem presentation (Lightowlers et al., 2015).   
 
 
Figure 1. Schematic illustration of the mitochondrion. The mitochondrial structure is defined by the presence of 
outer and inner membranes, with cristae in the inner membrane and the matrix where the mitochondrial DNA is 
present. 
 
1.2.1 Structure of the mitochondria 
In 1898, the name mitochondrion was introduced. The origin of the name is from the Greek 
words, "mitos" (thread) and "chondros" (granule) (Ernster and Schatz, 1981). Mitochondria basic 
structure is characterized by an outer (OMM) and inner membranes (IMM). These membranes 
enclose the intermembrane space (IMS) and matrix compartments, respectively form 
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mitochondria. Mitochondria is the only organelle in mammalian cells that carry its circular 
genome, mitochondrial DNA. Mitochondrial DNA is organized into nucleoids in the mitochondrial 
matrix (Nunnari and Suomalainen, 2012) (Fig. 1). 
The outer membrane allows the traffic of small molecules and ions as large as 5kDa. However, in 
this membrane, an important channel is located, the voltage-dependent anion channel (VDAC). 
The primary function of this channel is as a gatekeeper for the exit and entry of mitochondrial 
metabolites, regulating the cross-talk between the rest of the cell and mitochondria (Shoshan-
Barmatz et al., 2010).  
The inner membrane has a larger surface area compared to the outer membrane. One of the 
main characteristics of the IMM is the presence of features referred to as cristae (literally, crests). 
Initially, cristae were thought to be simple infoldings of the inner membrane (Frey and Mannella, 
2000). However, during the 1990s, Mannella et al., employing electron tomography 3D 
reconstruction, showed that the cristae are a bag-like structure (Mannella, 2006). This 
conformation suggests that cristae are specialized compartments for limiting the diffusion of 
molecules necessary for the respiratory chain (Cogliati et al., 2016). The cristae membrane is 
enriched in proteins involved in protein synthesis and translocation, in iron-sulfur biogenesis, and 
mitochondrial nucleoid maintenance (Vogel et al., 2006), and houses assembled respiratory chain 
complexes and supercomplexes (Cogliati et al., 2013). The density of proteins in this membrane 
is approximate of 75% by weight and the lipid content of 25%, making the cristae membrane one 
of the densest protein membranes in all biological membranes (Pernas and Scorrano, 2016).  
The space delimitated by the membranes is the IMS and the matrix. Due to the pH gradient (ΔpH) 
between the matrix and the IMS, protons are pumped from the matrix to the space formed inside 
of the cristae (cristae space). The cristae space is needed for the synthesis of ATP in the 
mitochondria (Friedman and Nunnari, 2014). Most of the metabolic processes carried out by the 
mitochondria take place in the matrix, such as Krebs cycle, one-carbon metabolism, and fatty 
acid oxidation(Ducker and Rabinowitz, 2017; Röhrig and Schulze, 2016). 
When observed the mitochondria in live cells, it can be seen that their morphologies are not 
static. The combined actions of fusion, fission, and motility modulate continuously the 
mitochondrial shape (Youle and van der Bliek, 2012). This structure formed is denominated 
mitochondrial network, which is very dynamic. Typical conformations are fluctuating between a 
tubular continuum, and a fragmented state(Benard et al., 2007). Changes in the mitochondrial 
network play a crucial role in apoptosis, Ca2+ transfer, and mitochondrial quality control 
(Rambold et al., 2011). 
Large guanosine triphosphatases (GTPases) mediate the process of mitochondrial fission and 
fusion (Hoppins et al., 2007). The fission process is mediated by a cytosolic dynamin family 
member (dynamin-related protein 1 (DRP1)). DRP1 constricts to sever both inner and outer 
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membranes when is recruited from the cytosol to form spirals around mitochondria. In 
mammals, four mitochondrially localized adaptor proteins play essential roles in the recruitment 
of DRP1 to mitochondria: mitochondrial fission factor (MFF); mitochondrial dynamics proteins of 
49 kDa and 51 kDa (MiD49 and MiD51); and fission 1 (FIS1), (Pernas and Scorrano, 2016). After 
GTP hydrolysis, DRP1 helix constricts, and the mitochondrion is divided. 
Fusion is a process that requires that two mitochondria get close enough to contact for the 
initiation (Meeusen et al., 2004). Once this contact is initiated, the dynamin-related OMM 
proteins, Mitofusin 1 and Mitofusin 2 (MFN1 and MFN2) form in trans, homotypic or heterotypic 
complexes (Koshiba et al., 2004) between neighboring mitochondria mediating the OMM fusion. 
Nevertheless, recently, MFN2 was described to be necessary for the ER-mitochondrial contact 
sites (Filadi et al., 2018). Next, OPA1 mediates the IMM fusion in a process dependent on inner 
membrane potential (Chan, 2012). The fusion of a ‘less fit’ mitochondrion with a ‘healthy’ 
mitochondrion is proposed to be part of a mechanism to maintain a healthy mitochondrial 
population. The role of the fusion process is to maintain genetic and biochemical homogeneity 
by permitting the dilution of superoxide, mutant DNA, and repolarization of the membranes 
(Pernas and Scorrano, 2016). In this way, mitochondrial fusion is a necessary process, which 
compensates for mutations in mitochondrial DNA, thereby allowing mitochondria to share 
components as long as the mutation load remains below thresholds of 80% to 90% per cell 
(Nakada et al., 2001). 
1.2.2 Mitochondrial DNA 
The mtDNA is a gene-dense, double-stranded DNA (dsDNA) molecule of 16.6 kb, which encodes 
11 messenger RNAs (mRNAs) (translated to 13 proteins), 2 ribosomal RNAs (rRNAs) (12S and 16S 
rRNA), and 22 tRNAs (Gustafsson et al., 2016)(Fig. 2). The OXPHOS system that consists of 
approximately 100 proteins, 13 subunits are encoded in the mitochondrial DNA. However, if the 
expression of the subunit encoded in the mtDNA is not optimal, OXPHOS collapse (Larsson et al., 
1998). On the contrary, to nuclear DNA, mtDNA consists of a circular structure and lacking intron-
exon structure. The replication of mtDNA is regulated by the displacement loop (D loop), a single 
non-coding region. Even though several copies of mtDNA are present within each cell, the total 
amount of mtDNA can vary between hundreds to thousands of copies according to the cell type 





Figure 2. Human mitochondrial genome. Mitochondria has his genome, in human cells, consist in a circular double-
stranded DNA molecule of 16.6 kb. The outer circle corresponds to the H-strand carrying most of the genes; the 
inner circle is the L-strand. It includes a 1.1-kb non-coding region. Adapted from (Gorman et al., 2016). 
Recently, it has been discovered in mammalians cells by super-resolution microscopy experiment 
the structure of the mitochondrial DNA nucleoid. The structure of the mtDNA consists of 
compacted DNA into nucleoid structures with a mean size of approximately 100 nm (Brown et 
al., 2011). Most nucleoids are formed by just one single copy of mtDNA. The main packing factor, 
considered the histone-like protein of mtDNA, is the mitochondrial transcription factor A 
(TFAM)(Kukat et al., 2011). Several molecules of TFAM binding one mtDNA molecule hence 
regulating the compaction of the nucleoid (Picca and Lezza, 2015). For example, Jakobs and 
colleagues (Kukat et al., 2011) reported approximately 1000 TFAM molecules per mtDNA 
molecule in human fibroblasts.  
The two strands of mtDNA, which were identified initially by density ultracentrifugation, are 
named the heavy (H) and light (L) strands (Clayton, 1982). Leading promoter for the transcription 
of each strand denominated the L strand promoter (LSP), and the H strand promoter (HSP) are 
present in the mammalian mtDNA. Three proteins are essential for the basal transcription 
initiation: RNA Polymerase Mitochondrial (POLRMT), TFAM, and the mitochondrial transcription 
factor B2 (TFB2M) (Hällberg and Larsson, 2014). 
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The replication and repair of mtDNA are done by mtDNA polymerase γ (POLG). This protein works 
in conjunction with several additional replisome components including topoisomerase, Twinkle, 
a mitochondrial RNA polymerase (mtRNAP), RNaseH1, mitochondrial single-stranded DNA-
binding protein (mtSSB), and mitochondrial DNA ligase III (Young and Copeland, 2016). Similar to 
the replication of nuclear DNA, the role of primase for the replication is done by mitochondrial 
RNA polymerase (mtRNAP) (Picca and Lezza, 2015). 
One of the first models described for the mtDNA replication, displacement loop model (strand-
displacement model), was proposed in 1972 (Robberson and Clayton, 1972). This model had been 
widely accepted to be the only mechanism of mammalian mtDNA replication. By the year 2000, 
a new model was proposed; in this case, mtDNA replication intermediates (RIs) were noticed that 
had properties of conventional, coupled leading- and lagging-strand DNA synthesis in tissue and 
cultured cells of human and mouse (Holt et al., 2000). In the years following, it was suggested 
that mtDNA replication could start at either one of the two sites. One of these sites is the OL site, 
and another one around approximately 13 Kb nucleotides, inside of the ND5 gene of the L-strand. 
DNA synthesis spreads in the leading strand, simultaneously incorporating RNA throughout the 
lagging strand (RITOLS)(Yasukawa and Kang, 2018). 
 
1.2.3 Mitochondria in metabolism 
Mitochondria have several vital roles in cellular metabolism. They are an essential producer of 
building blocks for biosynthetic pathways. For example: synthesis of nucleotides, in which the 
one-carbon metabolic pathway is involved; amino acids synthesis including glutamate, alanine, 
proline, and aspartate (Ducker and Rabinowitz, 2017); production of acetyl-CoA for fatty acids 
synthesis  (Hatzivassiliou et al., 2005); and glucose synthesis since the initial enzyme for 
gluconeogenesis, pyruvate carboxylase, is located in the mitochondria (Bahl et al., 1997).  
However, one of the most studied roles of mitochondria is the production of energy. 
Mitochondria integrates the fuel metabolism to generate energy in the form of ATP by oxidizing, 
fatty acids (Röhrig and Schulze, 2016), amino acids to give electrons onto the carriers NADH and 
FADH2 (DeBerardinis and Cheng, 2010), and pyruvate (derived from lactate or glucose) (Heiden 
et al., 2009). 
1.2.3.1 Glucose metabolism 
Glucose has an essential role in the metabolism of organisms. The importance of glucose in 
energy production is based on it relatively rich in potential energy, making it a proper fuel. The 
oxidation of glucose to water and carbon dioxide generates -2,840 kJ/mol (Boyle, 2005). This 
reaction starts in the cytoplasm with a process called glycolysis, where glucose is oxidized to a 
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three-carbon compound, pyruvate. The next two steps for the oxidation of pyruvate take place 
in the mitochondria, via the TCA cycle and the respiratory chain. 
1.2.3.1.1 Glycolysis 
The metabolic pathway that converts glucose into pyruvate is called glycolysis. These set of 
reactions take place in the cytoplasm and generates adenosine triphosphate (ATP). The glycolysis 
pathway comprises ten steps of chemical reactions, each catalyzed by a specific enzyme (Li et al., 
2015). During this process, three types of chemical reactions are particularly notable: (1) 
degradation of glucose to produce pyruvate, (2) production of ATP by phosphorylation of ADP to 
ATP, and (3) production of NADH. The final product of glycolysis, pyruvate, is oxidated to acetyl-
CoA by process of oxidative decarboxylation. The acetyl group is then fully oxidized to CO2 by the 
TCA cycle (Boyle, 2005). 
1.2.3.1.2 Citric acid cycle  
The citric acid cycle (also known as tricarboxylic acid (TCA) cycle or the Krebs cycle) was 
discovered by Hans Adolf Krebs in 1937. All the aerobic processes in animal tissue obtain energy 
from this primary metabolic pathway. The enzymes involved in the citric acid cycle are located in 
the mitochondria (Nazaret et al., 2009). Acetyl-CoA could be obtained from glucose via glycolysis 
or from fatty acids that have gone through β-oxidation. During the TCA, citrate is oxidated into 
isocitrate by aconitase. Isocitrate dehydrogenase by a decarboxylation reaction converts 
isocitrate to α-ketoglutarate (αKG). In this way, each new turn in the cycle provides a significant 
new amount of cellular ATP (Akram, 2014). The cycle only generates one molecule of GTP per 
cycle (during the conversion of succinyl-CoA to succinate). However, nicotinamide adenine 
dinucleotide (NAD+) and flavin adenine dinucleotide (FAD) is reduced to obtain NADH and FADH2 






Figure 3. Products of one turn of the citric acid cycle. At each turn of the cycle, two CO2 are released in oxidative 
decarboxylation reactions. The energy production is obtained from the three NADH, one FADH2, and one GTP (or 
ATP). Even though the schematic representation of the cycle shows the reaction in only one way, the reactions are 
reversible. Figure adapted from (Boyle, 2005) 
 
1.2.3.2 Respiratory chain 
Most of the cellular ATP is produced in the mitochondria, more specifically in the cristae that 
contain the ATP synthase enzyme. In the same membrane is located the large protein complexes 





Figure 4. The functional features of the mitochondrial respiratory chain and oxidative phosphorylation system.  
The black arrow represents the transfer of electrons produced by oxidation of NADH and succinate by complex I and 
II, respectively. Q: ubiquinone, C: Cytochrome c. Figure adapted from (Suomalainen and Battersby, 2018) 
 
During the citric acid cycle, a large amount of NADH and FADH2 are generated. Nevertheless, 
these molecules can be generated in other metabolic pathways and are used in the respiratory 
chain. NADH is oxidized by Complex I; in this process, electrons are transported through flavin 
mononucleotide (FMN), and multiple iron-sulfur (Fe–S) centers present in Complex I till they are 
transferred to coenzyme Q10 (CoQ10). Complex II and the FADH2 generated by β-oxidation 
donate electrons to CoQ10. This coenzyme carries the electrons to Complex III. Once in Complex 
III, electrons pass from the cytochrome b to cytochrome c1, and at the end to Fe–S components. 
Cytochrome c (Cyt C) is responsible for the transference of electrons from Complex III to Complex 
IV. Inside Complex IV, the electrons are transferred from the copper centers and cytochromes to 
O2 molecules to generate H2O finally. The energy obtained from the respiratory chain is used to 
actively pump protons through Complexes I, III, and, IV; from the mitochondrial matrix to the 
intra-cristae space. Finally, ATP is synthesized in Complex V as a consequence of the resulting 
electrochemical gradient because the gradient forces protons to move back through a proton 
channel in this complex (Alberts, 2014; Boyle, 2005; Chance and Williams, 2006; El-Hattab and 
Scaglia, 2016) (Fig. 4). 
 
1.2.4 Mitochondrial communication 
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The production of energy by the respiratory chain and different metabolites synthesized in the 
TCA cycle gives to mitochondria a crucial role in diverse biological processes. Such as cellular 
proliferation, differentiation, and adaptation to stress (Chandel, 2015). Mitochondria can alter 
the expression of nuclear genes through signals, thus modifying the function of the cell and 
reprogramming the metabolism. This kind of response is present in all organism, but the nature 
of the pathways involve, and the regulation varies. Depending on the trigger, the different 
pathways can be classified into Ca2+ dependent, energetic stress, and reactive oxygen species 
(ROS) stress responses (Jazwinski, 2013). 
In mammals, alterations in mitochondrial metabolism activate several pathways. For example, a 
reduction in ATP synthesis activates AMP-activated protein kinase (AMPK), which activates the 
mitochondrial biogenesis (Garcia-Roves et al., 2008). AMPK activated triggers changes in the 
expression of genes of mitochondrial proteins (Kelly, 2004). Additionally, the mitochondrial 
quality control system is activated by AMPK (Egan et al., 2011). 
Reactive oxygen species (ROS) are mostly produced during the process of oxidative 
phosphorylation. Complexes I and III can prematurely reduce oxygen, generating superoxide 
anion (O2 •-) (Murphy, 2009). Additionally, H2O2 is produced from the dismutation of superoxide 
(Wong et al., 2017). The mitochondrial ROS was always considered as a mere result of the 
inefficiencies of the OXPHOS. Nevertheless, it has emerged a critical role for mitochondrial ROS 
in the diffusion of cellular signaling pathways (Hamanaka and Chandel, 2010). Recent evidence 
suggests, for example, a role of H2O2 emitted from mitochondria during hypoxia. Since H2O2 can 
induce hypoxia-inducible transcription factors (HIFs), it has been identified as a central upstream 
regulator of many processes related to hypoxia (Waypa et al., 2006). Additionally, cellular survival 
and proliferation in cancer cells were reported due to the activation of NF‑κB, activated by 
mitochondrial ROS (Formentini et al., 2012). Furthermore, the mitochondrial biogenesis and 
expression of OXPHOS genes are induced by ROS via JNK–PGC1α signaling (Chae et al., 2013). 
Another essential role of mitochondria is the regulation of intracellular calcium levels (Rizzuto et 
al., 2012). Under a condition in which the mitochondrial DNA is damaged or malfunction of 
electron transport chain complexes, it triggers the loss of membrane potential and the further 
release of Ca2+ into the cytoplasm (Amuthan et al., 2002).  
Changes in the mitochondrial Ca2+ uptake is a significant cause of cell death, for this process is 
required the mitochondrial permeability transition pore (mPTP).  During the formation of the 
mPTP, a nonspecific high-conductance channel is formed in the inner membrane allowing the 
movement of solutes up to 1 KDa unrestrictedly (Brenner and Moulin, 2012). This process 
generates a collapse of the membrane potential, mitochondrial swelling because of the osmotic 
influx of water, and ATP hydrolysis in Complex V(Bhosale et al., 2015). In the case of the rupture 
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of the outer membrane due to the swelling several pro-apoptotic factors are released, such as 
cytochrome c (Bernardi et al., 2015; Bonora et al., 2015; Chinopoulos and Szabadkai, 2014). 
 
1.2.5 Mitochondria in pathology 
Mitochondrial diseases are characterized by a dysfunction in mitochondrial function generated 
by genetic disorders. These disorders are produced by mutations in mitochondrial or nuclear 
DNA, making the mitochondrial diseases a complex pathology (Nunnari and Suomalainen, 2012). 
For this reason, the observed phenotype is different in each patient. These diseases are reported 
to occur at any age and manifesting a variable range of clinical symptoms. They can affect any 
tissue or organ; in most of the cases, multiple systems are affected. The most common organs 
affected are reliant on aerobic metabolism (McFarland et al., 2010). Currently, mitochondrial 
disorders cannot be cured but can be treated. Most of the existing treatments are directed to 
boost mitochondrial biogenesis such as administration of bezafibrate (an agonist of PPAR), 
activation of AMPK by AICAR( 5-aminoimidazole-4- carboxamide ribonucleotide) or a ketogenic 
diet (Suomalainen and Battersby, 2018). These treatments increase mitochondria biogenesis, 
lipid oxidation, and in mitochondria myopathy, have been shown to improve muscle metabolism 
(Viscomi et al., 2011). 
Mitochondrial protein synthesis machinery or subunits of the respiratory chain are the most 
commonly affected by mutations producing the pathologies. There are three types of mutations 
in the mtDNA causing mitochondrial diseases: the one that affects the protein synthesis (for 
example, mutations in mitochondrial tRNA or rRNA), affecting structural proteins for the 
mitochondria (for example, mitochondrial mRNA mutations) or rearrangements in the 
mitochondrial DNA (for example, sporadic, single, large-scale mtDNA deletions) (Gorman et al., 
2015).  
The most well-characterized childhood mitochondrial disorder is Leigh syndrome, affecting 1 in 
40000 newborns in the USA (Cherezov et al., 2013). The pathology of has a significant variation 
between patients according to the age. Most commonly, patients present neurological symptoms 
such as ataxia, regression, and developmental delay. Although the symptoms can be 
multisystemic affecting the heart, liver, digestive system, and renal system (Lake et al., 2016). 
More than 75 genes mutations are associated with Leigh syndrome, and most of the mutated 
genes are components of the mitochondrial respiratory chain (Gorman et al., 2016). 
Nevertheless, the most frequent mutation associated to this syndrome is a mutation in the 
complex I; specifically, in NADH dehydrogenase (ubiquinone) Fe-sulfur protein 4 (NDUFS4) is the 
most frequent cause (Lake et al., 2016). For this reason, the Ndufs4 KO mice will be used as a 
model of mitochondrial dysfunction in this study 
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1.3 Lysosomal biology 
In the 1950s, Christian de Duve experimented with tissue fractionation, aiming to analyze the 
intracellular distribution of rat liver enzymes (de Duve et al., 1955). Upon realizing that five acid 
hydrolase enzymes were located in the same membrane-limited structure, it was suggested that 
these organelles were involved in intracellular digestion and hence named lysosomes (Greek for 
“digestive body”) (de Duve, 2005).  
During the observation of lysosomes with electron microscopy, it was determined that up to 5% 
of the intracellular volume correspond to lysosomes and that the morphology and size vary 
according to cell type. Additionally, it is observed the presence of electron-dense deposits 
(Holtzman, 1989). These organelles contain about 60 different degradative acidic enzymes. The 
enzymes digest different macromolecules such as DNA, RNA, proteins, polysaccharides, and lipids 
(Kolter and Sandhoff, 2005). All the lysosomal enzymes are acid hydrolases. In case of the 
lysosomal membrane brakes, the enzymes would be unable to degrade the cytoplasmic content 
protecting the cell from digestion. Mutation of the hydrolytic enzymes produces more than 30 
different human genetic diseases. All these diseases are characterized by the presence of 
accumulated undigested materials inside of the lysosome, and because of that, they are called 
lysosomal storage diseases (LSD) (Cooper, 2000). 
Few years after lysosomes were discovered, they were associated as a critical component of the 
two major degradative processes in the cell: endocytosis and autophagy. In the endocytosis, the 
lysosomes are the terminal degradative compartment, and in autophagy, the intracellular is 
degrade inside of the lysosomes (de Duve, 1983). In the last years, it has become clear that the 
lysosome does not merely function as a recycling center. This organelle is gaining prominence as 
a signaling hub for nutrients, with the v-ATPase playing an important role in sensing amino acid 
availability (Carroll and Dunlop, 2017). 
 
1.3.1 Structure of the lysosome 
Lysosomes are typically spherical with diameter between 100 nm and 500 nm. At the 
ultrastructural level, multilamellar structures have been described inside of the lysosomes. These 
structures are formed as a result of the partial degradation vesicle membrane that has been 
delivered to the lysosome (Kolter and Sandhoff, 2010). The lysosomal membrane consists of a 
single membrane, in which several integral membrane proteins necessary for functions such as 
the lysosomal structural integrity (Fig. 5). The limiting outer membrane is composed of a 
phospholipid bilayer of 7-10 nm that is decorated with transmembrane proteins. Lysosome-
associated membrane proteins (LAMP)1 and LAMP2 are the most abundant of proteins in the 
membrane, which together constitute about 80% of the membrane proteins (Saftig and 
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Klumperman, 2009). LAMP proteins and others, such as lysosomal integral membrane protein 2 
(LIMP2) and CD63, are heavily glycosylated on their luminal side and form the glycocalyx. This 
barrier protects the membrane from the action of the enzymes inside the lysosomal lumen (Saftig 
and Klumperman, 2009; Settembre et al., 2013). The presence of the v-ATPase, which pumps H+ 
ions to the lysosomal lumen generates membrane potential. The membrane potential is kept, by 
the export of cations, and import of anions. In this form, the ATPase activity is maintained 
(Mindell, 2012). Additionally, several lysosomal ion channels have been described, such as 
mucolipins, TRP channels (TRPMLs), and two-pore channels (TPCs)(Patel and Docampo, 2010; Xu 
and Ren, 2015). 
 
Figure 5. Electron micrograph of mouse embryonic 
fibroblasts illustrating electron-dense lysosomes. In 
the image, two lysosomes of different sizes are 
shown. The presence of multilamellar structures in 
the lysosomes can be observed. The image was 





1.3.2 Lysosomal function 
The most recent studies about the lysosome are focused on its role as a central signaling hub that 
governs cell growth, division, and differentiation (Lawrence and Zoncu, 2019). Plasma membrane 
receptors, extracellular material, and intracellular material are all processed by the lysosomes. 
Lysosomes are involved in two of the major processes of degradation for the cell: endocytosis, a 
significant mechanism of cargo delivery destined for degradation, and autophagy, a process in 
which the intracellular material is degraded. The final destination of most of the macromolecules 
is to be digested by the lysosomal hydrolytic enzymes(Kilpatrick et al., 2015). 
1.3.2.1 Lysosomal degradation of extracellular material 
Once the lysosomal proteins (membrane proteins and enzymes) are synthesized in the 
endoplasmic reticulum, lysosomal proteins traverse the Golgi complex to enter the trans-Golgi 
network (TGN), where the majority of lysosomal enzymes are directly sorted to the 
endolysosomal complex. These enzyme-containing lysosomes will later fuse with endocytic 
vesicles for the degradation of their cargo. There are several distinct subtypes of endocytic 
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vesicles that bud from the plasma membrane and mediate entry to the cell (Kumari et al., 2010). 
According to their different functions and role in the endocytic pathway, three main endosomes 
have been reported: early, recycling, and late (Huotari and Helenius, 2011). 
Endocytosis frequently starts when clathrin-coated pits formed in the plasma membrane bud 
into vesicles. Immediately after this process, the vesicles fuse with previously formed early 
endosomes under the control of the small GTPase Rab5 (Laifenfeld et al., 2007). Early endosomes 
act as a sorting station, allowing the newly empty receptors to return to the plasma membrane 
for later use, and directing the now free ligands molecules towards the lysosomes for degradation 
(System and Klumperman, 2015). When the endocytosis is regulated by Rab4 and Rab11, the 
receptor together with the membrane-bound lipids send to recycling endosomes and returned 
to the plasma membrane (Hsu and Prekeris, 2010). 
After the early endosomes are formed, internal vesicles start to bud towards the luminal side of 
these early endosomes. The number of vesicles formed increases, and thus constitute an 
essential step of maturation for the early endosome. In this process, the multivesicular bodies 
(MVB) are formed. The maturation process of the MVB is associated with changes in the presence 
of Rab proteins. Early endosome has Rab5 and late endosomes Rab7 (Poteryaev et al., 2010). The 
last stage in the endocytosis is the fusion of the late endosomes with the lysosomes. As a 
consequence of the fusion, the macromolecules inside the endosomes and intraluminal vesicles 
are degraded. 
During the endolysosomal pathway, it has been shown that the luminal pH decreases, and the 
amount of hydrolases increases. Although not all enzymes are active against all substrates in the 
lysosomes and the activity of each enzyme varies (Hu et al., 2015; Pillay et al., 2002). 
1.3.2.2 Lysosomal degradation of intracellular content 
Autophagy is defined as a conserved catabolic process that is vital for cellular homeostasis. By 
this process, the cell recycles intracellular macromolecules and organelles and improves the 
lysosomal degradation. It has been described so far three different types: chaperone-mediated 
autophagy (unique molecules are selected for degradation into the lysosome by chaperones), 
microautophagy (cytoplasmic components are directed into the lysosomes), and 
macroautophagy (cytosolic components are degraded by sequestration into a double-membrane 
vesicle named autophagosome that later fuses with lysosomes)(Hansen et al., 2018) (Fig. 6).  
Microautophagy is a non-selective process for molecules degradation in which the selection of 
cargo to the lysosomal limiting membrane. During this process, the lysosomal membrane is 
arbitrarily invaginated and converted into the autophagic tube, which encloses a portion of 
cytosol. This process is important for the cell; however, the underlying mechanism is still not 
precise (Li et al., 2012). In the case, the proteins are recognized by the chaperone due to the 
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presence of a KFERQ motif ( chaperone-mediated autophagy). In the cytoplasm, the heat shock 
cognate 71 kDa protein (HSC70) recognizes these motifs and recruits the substrate onto the 
lysosomal membrane surface. After that, the complex chaperon-protein bind to LAMP-2A and 
the complex is transferred inside the lysosome (Kaushik and Cuervo, 2018). 
The process of macroautophagy is mediated by several autophagy-related (ATG) proteins. It can 
be divided into at least five consecutive steps: initiation that can be induced by nutrient 
starvation. After that, the double membrane is formed with a shape of a cup and phagophore is 
formed. Next, the phagophore is expanded in the cytoplasmic cargo is sequester. In the next step, 
the phagophore fuse itself forming a structure known as autophagosome which lately fuses to 
the lysosome. The final step, it is the degradation of sequestered cargo inside of the 
autolysosome (Hansen et al., 2018). 
 
 
Figure 6. The macroautophagy process. Macroautophagy consists of several steps: (1) initiation induced by nutrient 
starvation (mTORC inhibits the initiation complex, and AMPK activates it), (2) when the process is active a double 
membrane structure is formed (membrane nucleation) with a cup-shape form leading to phagophore formation. (3) 
Phagophore expansion produces the formation of the autophagosome where the macromolecules are sequestered. 
After the autophagosome formation, the autophagosome fuse with the lysosome (4) generating the degradation (5) 
of the material inside the autolysosome. The autophagy process is regulated by multiple ATG proteins. Figure 
adapted from (Hansen et al., 2018). 
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1.3.2.3 Lysosome in nutrient sensing 
Beyond its role in cellular metabolism through the degradation of macromolecules, the lysosome 
has emerged as an integration hub for signal transduction, especially in the cellular metabolism 
and nutrient sensing. It has been discovered that mammalian target of rapamycin (mTOR) protein 
kinase, one of the master growth regulators, is recruited to the lysosome in response to nutrients 
in yeast and mammalian cells(Yang et al., 2017).This discovery center the lysosome as in 
integration hub for the cellular metabolism. 
At least two pools of amino acids are needed for the activation of mTOR complex 1 (mTORC1): (i) 
the cytoplasmic pool and (ii) the pool of amino acids produced from the degradation of 
macromolecules within lysosome/ vacuole (Perera and Zoncu, 2016). Cytoplasmic amino acids 
are sensed by SAMTOR, Sestrin, and CASTOR. These proteins modulate the activity of mTORC1 in 
according to the availability of to their ligands arginine, S-adenosylmethionine, and leucine, 
respectively (Kim and Guan, 2019). In addition to the cytoplasmic sensing of amino acids pool, 
mTORC1 senses the lysosomal amino acids availability interacting with its components in the 
lysosomal transmembrane. For example, it senses amino acids through v-ATPase and another 
amino acid transporter, called sodium-coupled neutral amino acid transporter 9 
(SLC38A9)(Wyant et al., 2017). Additionally, new evidence suggests that mTORC senses the 
inputs from glucose and cholesterol. In the case of cholesterol and arginine, mTORC1 is activated 
by SLC38A9; in this way, a multi-mode nutrient integration is possible (Castellano et al., 2017). 
Once mTORC1 is active at the lysosomal membrane, it activates S6-kinase by phosphorylation, 
promoting the biosynthesis of lipids (Caron et al., 2015), and nucleotides (Robitaille et al., 2013). 
Also, it promotes a switch metabolism towards the use of glucose and ribosomal biogenesis 
(Jastrzebski et al., 2007). Simultaneously, the activation of mTORC1 results in the inhibition of 
two critical initiators of the autophagosome formation (ULK1 and Atg13 protein)(Shen and 
Mizushima, 2014). Also, on the lysosomal membrane, mTORC1 inhibits the MiT/TFE factors 
transcription factor EB (TFEB), TFE3, TFEC, and microphthalmia-associated transcription factor 
(MiTF) by phosphorylation. These transcription factors have been shown to play a crucial role in 
the autophagic gene expression and lysosomal biogenesis(Martina et al., 2016; Napolitano and 
Ballabio, 2016). 
1.3.3 Lysosomal storage diseases 
As before mentioned, mutations in genes that encode lysosomal hydrolases can cause several 
disorders in the body. Theses pathologies constitute a group of diseases named lysosomal 
storage diseases (LDSs). Also, some of these disorders can be caused by mutations in lysosomal 
membrane transporters or integral proteins of the membrane. (Futerman and Van Meer, 2004). 
Nowadays, there are more than 50 recognized LSDs. In most of the LSDs, It is observed in the 
lysosomes accumulation of substrates none degraded. Because of that, the LSDs are grouped 
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according to the chemical nature of the accumulated substrate. It has been reported that 
approximately 1 in 8000 live births are diagnosticated with one of these disorders, making LSDs 
one of the most common disorders compared to others rare diseases (Fuller et al., 2006). Because 
the accumulation of substrate occurs in several organs and systems, the phenotypes observed in 
the patients are diverse. It depends on the variable visceral association, hematological, ocular, 
skeletal, and neurological symptoms. Usually, LSDs disorders progress and evolve (Parenti et al., 
2013). 
The pathologies associated with the LSDs can cause impairments in other lysosomal-related 
pathways. In Pompe disease, for example, a progressive myopathy triggered by a deficiency in 
the enzyme acid a-glucosidase (GAA), leads to an expansion of the autophagic compartment. 
Another disease associated with impairment in autophagy is multiple sulfatase deficiency (MSD). 
In this case, the fusion between autophagosomes and lysosomes are affected. The primary 
source of this disease is a defective posttranslational activation of sulfatase-modifying factor 1 
(SUMF-1). One of the most studied cases of LSDs induced by a deficiency in the transport of 
substrates is Niemann-Pick disease (NP). There are three subclasses of Niemann-Pick disease. 
Initially, all of them were described as sphingomyelin-storage disorders. However, it was 
discovered that only Niemann-Pick types A and B are produced by the defective activity of 
sphingomyelinase. Niemann-Pick type C (NPC) is originated by a deficient transport of the 
cholesterol, that is caused by a deficient activity of NPC1 (cholesterol transporter) or by the 
inefficient binding of the soluble portion (NPC2 protein) to cholesterol in the lysosomal lumen 
(Futerman and Van Meer, 2004; Parenti et al., 2015). In this study, two main LSDs are relevant 
and will be discussed in the succeeding sections. 
1.3.3.1 Pompe´s Disease  
The disease was first discovered in 1932 by Johannes Pompe. Analyzing tissue samples of a child 
who died from cardiomyopathy, he observed ubiquitous deposition of glycogen in vacuoles (later 
known as lysosomes). By 1963, H. G. Hers classified this pathology as a glycogen storage disease 
type II and determined that the deposits were a consequence of the deficient activity of acid 
alpha-glucosidase (Cabello and Marsden, 2016). The main reason for this disease is mutations in 
the gene that encodes the acid alpha-glucosidase (GAA) enzyme. More than 300 variations of 
mutations in the gene have been detected, but the severity of the disease varies according to 
type of mutation and which region of the gene is affected (Kroos et al., 2008). 
One of the main characteristics of the disease is the presence in granules of lysosomal glycogen 
when cells are observed by electron microscopy. The glycogen accumulation could also be 
observed in the inter-fibrillar spaces and cytoplasm (Askanas et al., 1976). In some cases, the 
lysosomes can break, resulting in large “glycogen lakes,” which have been associated in the 
muscle with the pathology of fibrosis and loss of function (Griffin, 1984). Most recently, an 
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impairment in the autophagy process was reported in the Gaa -/- mouse model, and also in 
Pompe’s disease patients (Raben et al., 2009) proposing that defective autophagy may play a role 
in the disease. However, autophagy is not the only metabolic process affected by this disease. 
Reported abnormalities in the calcium homeostasis and inefficient mitochondrial activity were 
reported in Pompe´s disease (Lim et al., 2015). 
1.3.3.2 Cysteine cathepsins proteases 
In the lysosomes it has been shown the presence of more than 50 different enzymes, all of them 
are acid hydrolases responsible to the digestion of catabolites. Among these enzymes are the 
cathepsin (CTS) proteases. There are three main classes of cathepsins: aspartic cathepsins (CTS D 
and E), serine cathepsins (CTS A and G), and cysteine cathepsins that comprises 11 members (CTS 
B, C, F, H, K, L (CTSL1), CTSL2 (CTSV), O, S, W and Z (CTSX)(Cermak et al., 2016; Fonović and Turk, 
2014). 
Most of the cysteine cathepsins have an endopeptidase activity, cleaving the peptide bonds 
inside their protein substrates. Two of the cysteine cathepsins have an additional activity, CTSB 
(carboxypeptidase) and CTSH (aminopeptidase) and another two do not present endopeptidase 
activity, CTSC and CTSZ (Devanathan et al., 2005; Nägler et al., 1999). The enzymatically active 
site is formed by a histidine, a cysteine, and an asparagine residue. This three residue constitutes 
a classic acid-base-nucleophile triad. Additionally, it has been shown that most of these enzymes 
are glycosylated (Ghosh et al., 2003). 
Cysteine cathepsins are proteases conserved since prokaryotes, due that they belong to the 
superfamily of papain proteases (Olson and Joyce, 2015). Two members of this family, CTSB and 
CTSL have been linked to several diseases such as cancer, osteoporosis, infectious diseases, and 
rheumatoid arthritis (Ishibashi et al., 1999; Troen). In the context of cancer, it has been found 
that cells can secret CTSB and CTL into the extracellular space due to alterations in endolysosomal 
trafficking (Olson and Joyce, 2015). Once secreted cathepsins modified the tumor 
microenvironment degrading the extracellular matrix promoting the tumor invasion (Aggarwal 
and Sloane, 2014). Furthermore, it was reported that mice lacking both of these cathepsins 
present neurodegeneration and pronounced reactive astrocytosis (Felbor et al., 2002), two main 
hallmarks of Alzheimer’s disease and NPC. Another characteristic of these cathepsins is that their 




1.4 Biological membranes 
1.4.1 Structure of the membrane 
In 1972, Jonathan Singer and Garth Nicolson defined the fluid mosaic model which describes the 
dynamic and fluid nature of biological membranes. The analogy of the mosaic is represented by 
the proteins inserted into the fluid, which is the lipid bilayer. The bilayer allows the lateral 
diffusion of proteins and lipids through the membrane surface. Usually, lipids move faster than 
the proteins (Zimmerberg and Gawrisch, 2006) (Fig. 7). Conditions such as membrane 
composition and temperature affect the fluidity of the lipid bilayer. 
Figure 7. Model of the fluid mosaic. Proteins and lipids are essential components of the membranes. Hydrophobic 
lipid “heads” are facing the outside part of the membrane; meanwhile, the hydrophilic part is facing the inside 
forming a matrix where proteins are positioned; schematic three-dimensional and cross-section views (Singer and 
Nicolson, 1972).  
1.4.2 Lipid composition 
Biological membranes are formed mainly three different types of lipids: sterols, phospholipids, 
glycolipids. Phospholipids have two hydrophobic tails connected to glycerol and a polar head 
group containing a phosphate group. When the phospholipid has a three-carbon glycerol 
backbone, it is called phosphoglyceride. One of the most abundant phospholipids is the 
phosphatidylcholine (PC) (Fig. 8a), in which a choline molecule is liked to the phosphate group. 
Reemplazament of the choline with serine produces phosphatidylserine (PS). In case that the 
choline is replaced by ethanolamine, phosphatidylethanolamine (PE) is formed. The last group of 
lipids in the glycolipids that contain either glycerol or sphingosine and the phosphate head is 
replaced by a sugar such as glucose. (Fig. 8b). Sterols are essential for the composition of animal 
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membranes, being the most important the cholesterol. The structure of cholesterol is quite 
different compared to the other two groups. To four-ring steroid structure, a short hydrocarbon 
side chain and hydroxyl group (which is the hydrophilic ‘head’) are added (Fig. 8c) (Watson, 2015). 
 
 
Figure 8. Schematic representation of the three types of membrane lipids. The lipidic composition of the 
membrane, phospholipid content, and sterol content can be modified by mammalian cells. A) Phosphatidylcholine, 
B) Glycolipid, and C) a sterol. Figure adapted from (Watson, 2015). 
 
The distribution of lipids in the membrane is not random. Each organelle has a different lipidic 
composition. This composition affects the structure, shape, and function (Dowhan, 1997). The 
lipid composition of different organelles can be appreciated in the following table (Table 1): 
 
 




Lysosomes Golgi Plasma 
membrane
0.175 0.374 0.156 0.825 0.672
0.003 0.014 0.038 0.038 0.128
% of total phospholipids
44 60 48 51 40
34 23 17 21 24
5 10 6 12 8
1 2 3 6 9
14 1 1 1 1
<1 1 1 <1 1












One of the most studied membranes is the mitochondrial membrane. The main characteristics 
of the mitochondrial membrane are i) the proportion of lipids (phospholipid and sterol) to 
proteins are lower compared to other subcellular fractions. ii) About 80 % of the total 
phospholipids present in the membrane are phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE). iii) The membrane has a high content of cardiolipin (between 
10-15%). iv) The proportion of sphingolipids and sterols is low in this membrane. See Table 1. 
Since the membrane sterol content is also low, small changes in the sterol content in the 
membrane is critical. An increase of cholesterol requirement has been reported in cases of high 
cell proliferation (Bensinger et al., 2008; Lo Sasso et al., 2010) and tumor growth (Borena et al., 
2012; Clendening et al., 2010). In pathological conditions, cholesterol can be accumulated in the 
mitochondrial membranes modifying the membrane organization. The increase of cholesterol in 
the membrane alters the permeability and function of resident proteins (Maxfield and Tabas, 
2005). For example, increment in cholesterol content of the mitochondrial membrane has been 
observed in cases of cancer (Ribas et al., 2016) and lysosomal storage diseases (LSD), especially 
in Niemann Pick C (NPC type C) (Balboa et al., 2017). 
 
1.4.3 Cholesterol 
1.4.3.1 Structural importance of cholesterol in membranes 
The molecule of cholesterol (Fig. 9) is composed of a four-ring skeleton fused to a hydroxyl group 
at carbon 3 (Urich, 1994). The hydroxyl group is of great importance because it gives to 
cholesterol the amphiphilic character allowing the cholesterol molecule to orient in membranes 
(Bloch, 1983). The permeability properties of the lipid bilayer are enhanced when cholesterol is 
mixed with phospholipids (Cooper and Shattil, 1980). Cholesterol inserts into the bilayer with its 
hydroxyl group close to the polar head groups of the phospholipids (Ohvo-Rekilä et al., 2002). In 
this position, cholesterol decreases the mobility of the hydrophobic tails of the phospholipids 
(Yeagle, 1985). As a result, there is a reduction in the permeability of the membrane to small 
molecules water-soluble since the lipid bilayer became more rigid in this region (Needham and 




Figure 9. 2D structure of a cholesterol molecule. The essential hydroxyl group, which gives to cholesterol the 
orientation in biological membranes is in red. The structure was obtained from ChemSpider  
 
1.4.3.2 Cholesterol biosynthesis pathway 
There are two main ways to obtain cholesterol: (i) through the ingestion of particular food or (ii) 
de novo synthesis (Brown et al., 2018).  
i) Cholesterol is obtained by the ingestion of food of animal origin. Cholesterol and cholesteryl 
esters are delivered to many tissues by low-density lipoprotein (LDL) (Goldstein and Brown, 
2015). High- density lipoprotein (HDL) is responsible for the removal of free cholesterol and its 
transport to the liver (Brown and Goldstein, 1986). 
ii) The cholesterol biosynthesis could be studied as a process that consists of five major steps 
(Boyle, 2005): 1) acetyl-CoA is converted to mevalonate 2) mevalonate is used as a precursor of 
isoprenoid units 3) six isoprenoid units are condensed into squalene 4) the primary steroids 
structure if formed by squalene cyclization forming lanosterol 5) lanosterol is used to produce 
cholesterol (Fig. 10) (Cerqueira et al., 2016). 
Step 1) Synthesis of mevalonate from acetate: two molecules of acetyl-CoA are condensed to 
produce acetoacetyl-CoA catalyzed by cytosolic thiolase. The produced acetoacetyl-CoA is 
condensed with another molecule of acetyl-CoA in a new reaction. This process is catalyzed by 
HMG-CoA synthase. This new product is named HMG-CoA. In the last step of this stage, HMG-
CoA to mevalonate by HMG-CoA reductase (Fig. 10). In the last step, two molecules of NADPH 
donate two electrons. The conversion of mevalonate to HMG-CoA is the primary regulatory step 
in the cholesterol biosynthesis pathway (Clendening et al., 2010). Because of that, the inhibition 
of  HMG-CoA reductase with drugs is one of the most effective treatments to reduce cholesterol 
levels (Sharpe and Brown, 2013). 
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Step 2) Conversion of mevalonate to two isoprenes: mevalonate is phosphorylated sequentially 
by three different kinases: mevalonate kinase, phosphomevalonate kinase, and mevalonate 
pyrophosphate decarboxylase. Initially, the mevalonate is phosphorylated by the three different 
kinases to form an intermediate named 3-Phospho-5-pyrophosphomevalonate. From this 
intermediate, when the carboxyl and the phosphate group leave a new structure of double bond 
is produced. In this way, Δ3-isopentenyl pyrophosphate is formed, and the isomerization of the 
Δ3-isopentenyl pyrophosphate generates the other isoprene, dimethylallyl pyrophosphate (Fig. 
10). 
Step 3) Six molecules of activated isoprene are condensed forming squalene: dimethylallyl 
pyrophosphate and isopentenyl pyrophosphate are condensed, removing one phosphate group 
and forming a 10-carbon chain compound, geranyl pyrophosphate. This new molecule undergoes 
another condensation reaction with isopentenyl pyrophosphate, yielding a 15-carbon molecule, 
farnesyl pyrophosphate. In the last stage, two molecules of farnesyl pyrophosphate join to create 
squalene (Fig. 10) while removing both pyrophosphate groups. 
Step 4) Four-ring steroid nucleus is formed by squalene cyclization: the folding of squalene form 
a structure closely similar to the steroid nucleus. To be able to form the ring, squalene must be 
converted to squalene 2,3-epoxide by an oxidase, squalene epoxidase. Squalene 2,3-epoxide is 
cycled by lanosterol synthase resulting in lanosterol as the final product (Fig. 10). 
Step 5) Formation of cholesterol: the conversion of lanosterol to cholesterol consists on a series 
19-steps process catalyzed by nine different enzymes: two enzymes are employed in multiple 
steps, and three are used two times in the process. To obtain cholesterol, several methyl groups 




Figure 10. The mammalian cholesterol biosynthetic pathway. The synthesis of cholesterol from acetyl-CoA requires 
at least 20 enzymes. SREBPs regulate the expression of the genes encoding these enzymes. The four central 
intermediates (mevalonate, isopentenyl diphosphate, squalene, and lanosterol) are in bold. The primary genes 
studied during this thesis are in red brackets. Lipids structures were obtained from ChemSpider. 
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1.4.4 Regulation of cholesterol biosynthesis 
1.4.4.1 Sterol regulatory-element binding proteins (SREBPs). 
Sterol regulatory-element binding proteins (SREBPs) are a conserved family of transcription 
factors that regulates the expression of genes necessaries for the lipid homeostasis according to 
requirements of each species. In mammals, there are three different isoforms of SREBP: SREBP-
1a, SREBP-1c, and SREBP2 (Brown and Goldstein, 1997). By alternative splicing of the same gene, 
SREBP-1a and SREBP-1c are generated (Horton et al., 2002). 
The network of genes regulated by SREBPs, regulate the activity of the transcription factor at 
multiple levels by feedback regulation (Hitoshi Shimano and Sato 2017). Each different SREBP 
protein has a determined physiological role. For example, lipid synthesis in rapidly growing cells 
is fully activated by SREBP1a, whereas SREBP1c is involved in fatty acid synthesis and energy 
storage (H Shimano et al. 1997; Toth et al. 2004). SREBP2 mostly regulates the transcription of 
genes related to cholesterol metabolism and mediates sterol regulation in every tissue (Horton, 
Goldstein, and Brown 2002). 
SREBPs are located in the membrane of the endoplasmic reticulum (ER), and the active form is 
generated once they are cleaved in the Golgi. Once active, they are transported to the nucleus 
by importin β. Although the normal process requires binding of the proteins to importins α and 
β, SREBPs can bind importin β even in without importin α. However, before entering the nucleus, 
the SREBP helix–loop–helix leucine-zipper domain needs to be dimerized (Nagoshi et al. 1999). 
When the complex is transported to the nucleus, it is fast degraded by the ubiquitin and 
proteasome pathway (UPS). It has been reported that cultured cells treated with proteasomes 
inhibitors showed an increase in the nuclear levels of SREBPs and its regulated genes (Hirano et 
al. 2001). In the nucleus, SREBPs associates with several transcriptional co-activators (e.g., CBP 
and p300). The interaction of these co-activators with SREBPs increase its transcriptional activity 
probably because the co-activators have an intrinsic histone acetyltransferase activity. The 
acetylation of SREBPs inhibits the degradation by the UPS (Giandomenico et al. 2003; Sundqvist 
and Ericsson 2003). 
1.4.4.2 Mechanism of activation of SREPBs 
SREBPs protein has two domains, NH2-terminal (transcription factor domain) and COOH-terminal 
(regulatory domain). Both domains are located in the cytosol and connected by a membrane-
spanning helix that flanks a short loop facing the ER lumen (Fig. 11). Immediately SREBP is 
synthesized in the ER membrane, the protein binds another ER membrane protein, SCAP (SREBP 
cleavage activating protein), through its COOH terminal domain in the cytosol (Hua et al., 1996). 
The location of SCAP in the ER membrane allows it to sense cholesterol in the membrane. SCAP 
has an N-terminal domain formed by eight transmembranes (TM) helices separated by 
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hydrophilic loops. The TM helices 2-6, are known as a sterol-sensing domain (SSD) (Nohturfft et 
al., 1998), bind a scaffold protein, Insigs (insulin-induced gene), in the ER membrane, in high 
cholesterol conditions (Yang et al., 2002). When the cholesterol proportion is more than 5% of 
total lipids of the ER membrane, it binds to the luminal loop 1 of SCAP. The binding promotes 
changes in the conformation of SCAP hiding the luminal loop 6, which is recognized by COPII 
proteins for transport to Golgi (Goldstein and Brown, 2015). Under this new conformation, the 
SCAP/SREBP complex is retained in the ER membrane preventing Golgi processing of SREBP (Fig. 
4). 
Conversely, when the cholesterol content drops to less than 5%, SCAP/SREBP complex exits the 
ER. In this condition, loop 1 of SCAP binds loop 7, thus exposing loop 6 (Brown et al., 2018). Once 
loop six is exposed, it binds COPII-coated vesicles that bud from ER membranes. The vesicles are 
transported to the Golgi (Fig. 5)(Radhakrishnan et al., 2008). SREBP in the Golgi membrane is 
cleaved in two different sites yielding the NH2-terminal domain (transcription factor domain) 
(Brown and Goldstein, 1997). 
 
 
Figure 11. Model of regulation of SREBP in ER membranes. Under conditions of high cholesterol in the cell, Insig-1 
binds to SCAP/SREBP complex retaining the complex in the ER membrane. However, in cases of low cholesterol, 
Insig-1 does not bind the complex SCAP/SREBP. Because of that, SCAP/SREBP are transferred to the Golgi, where 
SREBP is processed. Illustration based on (Goldstein et al., 2006). 
 
1.4.5 Control of lipids biosynthesis 
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Several transcription factors activated by extracellular stimuli have been reported to modulate 
the activity of SREBPs. For example, hepatocyte nuclear factor 4 (HNF4) and the liver X receptor 
(LXR) upon activation both nuclear receptors bind SREBPs regulating its activity. These nuclear 
receptors are activated by the binding of lipophilic ligands. The regulation of the lipid biosynthesis 
pathway by HNF4 and LXR generates an additional mechanism for the maintenance of lipid 
homeostasis maintenance (Kanayama et al., 2007).  
Lipogenesis is an anabolic process by which fatty acids are synthesized from acetyl-CoA. Insulin 
was discovered as a significant anabolic hormone that controls lipogenesis (Shimomura et al., 
1999). Initially, the activation of SREBP1 by insulin was identified to be regulated by PI3K and 
AKT, and these two kinases are induced by insulin (Krycer et al., 2010). Later, mammalian target 
of rapamycin (mTOR) emerged as a critical anabolic integrator that controls multiple cellular 
processes such as autophagy, cell growth, cell cycle, and cell survival (Zoncu et al., 2011). mTOR 
is a serine/threonine-protein kinase conserved through the evolution that is present in the cell 
as two different complexes mTORC1 and mTORC2 (Loewith et al., 2002). Both of them are formed 
from several proteins. mTORC1 contains mTOR, Raptor, mLST8, and PRAS40; meanwhile, 
mTORC2 is formed by mTOR, Rictor, mSin1, Protor, and mLST8 (Caron et al., 2015). The activation 
of mTORC1 is controlled by nutrient status and cellular energy. Meanwhile, mTORC2 is 
dependent on extracellular signals, mainly growth factors and cytokines, for the final activation 
of mTORC1 (Ebner et al., 2017). mTORC1 is an essential downstream hub of integration for the 
signaling pathways induced by insulin. It controls the three major nutritional pathways: 
protein,glucose, and lipid metabolism (Shimano and Sato, 2017).  
There are several molecular mechanisms involved in the activation of SREBPs signaling induced 
by insulin, for example, through AKT activation. Once active, AKT inhibits by phosphorylation the 
hepatic insulin-suppressive (INSIG) isoform INSIG2A reducing SREBP stability (Yabe et al., 2003; 
Yecies et al., 2011). However, there are other mechanisms in which AKT is not involved. One of 
them is through the activation of mTORC1 by the inhibition of TSC, being TSC an upstream 
inhibitor of mTORC1 (Porstmann et al., 2008). Another mechanism is that mTORC1 activation 
leads to phosphorylation and translocation from the nucleus of acid phosphatase lipin-1 ( lipin-1 
is an inhibitor of SREBP1) (Peterson et al., 2011). 
Another essential kinase for metabolism regulation is AMP-activated protein kinase (AMPK). The 
first metabolic pathway found to be regulated by AMPK was the lipids and sterol synthesis (Herzig 
and Shaw, 2018). AMPK is a conserved sensor of the energy supply and demand for the cell, and 
it modulates the growth of organs and cells (Hardie, 2007). This protein belongs to the family of 
AMPK-related kinase, which is constituted by 13 kinases in the human genome and all of them 
are serine/threonine-protein kinase. The AMPK is integrated by three different subunits, an α 
subunit, a β subunit, and a γ subunit. The catalytic subunit is α while β forms the scaffolding unit. 
A regulatory subunit involved in nucleotide binding is formed by the γ subunit (Sanz et al., 2013). 
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In mammals, there are multiple subtypes of each subunit, and they are differentially expressed 
according to the tissues. The catalytic subunit α has two different isoforms (α1 and α2), β have 
two (β1 and β2), and γ subunits three (γ1, γ2, and γ3) isoforms (Herzig and Shaw, 2018). 
In hepatocytes, AMPK can directly phosphorylate SREBP1c or SREBP2 (Li et al., 2011). AMPK 
phosphorylates SREBP1c at Ser372, inhibiting the cleavage and preventing nuclear translocation, 
and transcriptional activity; and ultimately suppress lipogenesis (Han et al., 2019; Li et al., 2011). 
AMPK regulates HMGCR (a vital enzyme of the de novo cholesterol biosynthesis pathway) by 
phosphorylation at Ser872, close to the C-terminus (Hardie et al., 1998). Its phosphorylation by 
AMPK represses cholesterol synthesis, a high energy consumption process (Mohamed et al., 
2015). It is worth pointing out that HMGCR is present in the cells in both forms, unphosphorylated 







Models of lysosomal and mitochondrial dysfunction have been intensely studied and the 
mechanisms underlying the crosstalk between these organelles, still rather elusive, have been 
the subject of interest of our research group (Fernandez-Mosquera et al., 2019; Yambire et al., 
2019). However, less is known about how the dysfunctions of these organelles modify the 
biosynthesis pathway of some biomolecules such as lipids. Lipids are essential components of 
cellular membranes and signaling (Jaishy and Abel, 2016). Therefore, this study focuses on the 
metabolism of cholesterol, especially in its biosynthesis pathway; exploring the independent 
roles of lysosomal and mitochondrial dysfunction in the biosynthesis of cholesterol. For this 
reason, we proposed the following aims: 
 
• Establish if the activity of cholesterol biosynthesis is sensitive to mitochondrial and 
lysosomal dysfunction. 
 
• Characterize transcript level changes of the main enzymes involved in cholesterol 
biosynthesis pathway in several models of mitochondrial and lysosomal dysfunction. 
 
• Determine changes in the total cholesterol content and unesterified cholesterol content, 
in the whole-cell and mitochondria, due to mitochondrial and lysosomal dysfunction. 
 
• Identify the main signaling pathways affected by mitochondrial or lysosomal dysfunction 







2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Consumables and Kits 
The consumables and kits used during this project are listed below, supplier and catalog 
number are included. 
Table 2. List of consumables and kits 
Product Supplier Catalog number 
Amersham Hybond PO45 PVDF GE Healthcare 10600023 
Amplex™ Red Cholesterol Assay Kit Thermo Scientific A12216 
Centrifuge tubes 15 mL Corning CentriStar Corning 430791 
Centrifuge tubes 50 mL Corning CentriStar Corning 430829 
Chloroform Merck 102442 
Cryomold (tissue tek) Fisher Scientific NC9511236 
CRYSTAL RNA Mini Kit New England Biolabs 31-010-404 
Cuvettes PMMA VWR-International 634-0678 
DMEM high glucose + pyruvate Gibco 41966-029 
DMEN high glucose Gibco 41965-062  
Fetal Bovine Serum Heat-Inactivated Gibco 10500-064 
High-Performance chemiluminescence 
film 
GE Healthcare 28906837 
iScrip cDNA Synthesis Kit Bio-Rad 170-8891 
Lenti X concentrator Clontech 631231 
Lipofectamine 2000 Reagent  Invitrogen 11668-019 
Luminata™ Classico Western HRP 
Substrate Millipore WBLUC0500 
Luminata™ Crescendo Western HRP 
Substrate Millipore WBLUC0500 
Luminata™ Forte Western HRP Substrate Millipore WBLUF0500 
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Luna® Universal qPCR Master Mix New England BioLabs M3003X 
Medical X-Ray Film Foma  
Microseal B seal Bio-Rad MSB1001 
PageRuler Plus Prestained Protein Ladder Thermo Scientific 26619 
PBS tablets Sigma Aldrich P44177-100TAB 
PCR plate 384-well skirted ABI-Type 
(Universal) 
StarLab E1042-3840 
Penicillin/Streptomycin Gibco 15140-062 
Pierce BCA Protein Assay Kit Thermo Scientific 23225 
Protein Assay Dye Reagent Concentrate Bio-Rad 500-0006 
Serological Pipette 10 mL StarLab E4860-1011 
Serological Pipette 25 mL StarLab E4860-2511 
Serological Pipette 5 mL StarLab E4860-0511 
Test Tube Soda Glass VWR-International 212-003 
Tips 10 pL TipOne StarLab S111-3210 
Tips 1000 pL TipOne StarLab S1111-6001 
Tips 20 pL TipOne StarLab S120-1810 
Tips 200 pL TipOne StarLab S1120-8800 
Triple Express (1X) Gibco 12605-010 
Trypan Blue 0.4% Life Technologies T10282 
Tubes 0.5 mL molecular probes Life Technologies Q33856 
Tubes 1.5 mL StarLab E1415-1500 
Tubes 2 mL StarLab S1620-2700 
Tubes 8 Twin Strip Start PCR StarLab 11402-3700 








List of reagents use during this study 
Table 3. List of reagents  
Product Supplier Catalog Number 
2-Mercaptoethanol Carl Roth 4227.3 
Absolute ethanol BD Bioscience 354052 
Acrylamide solution 40% AppliChem A0385 
Ammonium Persulfate (APS) AMRESCO 0486 
Antimycin Sigma Aldrich A8674 
Bovine serum albumin (BSA) Sigma Aldrich A7906 
Bromophenol blue Carl Roth T116.1 
CaCl2 Alfa Aesar L13191 
Chloroquine disphosphate Sigma Aldrich C6628 
Coomassie Brilliant Blue G Carl Roth 9598.2 
Cryo-OCT compound Fisher Scientific 14-373-65 
DMSO Sigma Aldrich D8418 
DTT AppliChem A2948 
EDTA Carl Roth 8043.2 
EGTA Sigma Aldrich E3889 
Ethanol 70% VWR 84858.440 
Filipin  Sigma Aldrich  F4767 
Glycerol Carl Roth 7530.1 
Glycine VWR 0167 
H2O Nuclease Free VWR E476 
HaltTM Protease & 
Phosphatase single-use 
Inhibitor Cocktail 
Thermo Scientific 78442 
HCl Sigma Aldrich H1758 
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HEPES Carl Roth HN77.2 
HPCD (2-Hydroxypropyl)-β-
cyclodextrin 
Sigma Aldrich H107 
K2HPO4 Carl Roth P749.2 
KCl Volu-Sol 83608.26 
KH2PO4 Carl Roth 3904.1 
Methanol VWR 20903.368 
MgCl2 VWR 8.14733.0100 
MgSO4 – 7H2O Sigma Aldrich 63138 
NaCI AppliChem A1430,0010 
NaH2PO4.H2O Carl Roth K300.1 
NaHCOs Carl Roth P029.3 
NaN3 Sigma Aldrich 52002-1006 
N-dodecylmaltoside Carl Roth CN26.2 
NH4CI Carl Roth K298.1 
Nonidet®P-40 Substitute AMRESCO E109-50ML 
PMSF Sigma P7626 
Rotenone Sigma R8875 
SDS Sigma Aldrich L4509-500G 
Skim Milk Powder Fluka 70166 
Sodium deoxycholate Sigma Aldrich 30970 
TEMED Sigma Aldrich T7024 
Torin-1 BioVision 2273 
TRI Reagent Sigma T9424 
Tris Base Sigma Aldrich T1503 
Tris-HCl Carl Roth 9090.2 
Triton X-100 AMRESCO 0694 
Tween 20 AMRESCO 0777-1L 
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U18666A Cayman 10009085 
 
2.1.3 Solution and buffers 
Solutions and buffers used during this study are listed below. All of them were prepared in 
ddH2O unless a different solvent is specified. 
Table 4. List of solution and buffers 
Buffer/solution Composition 
Blocking buffer 5% (w/v) Skimmed milk or BSA in TBST 
Freezing medium 
10%(v/v) DMSO, 20%(v/v) FBS in DMEM high 
glucose 
Mitochondria isolation buffer 250 mM Sucrose, 20 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 1 mM EGTA, pH 7.5 
NaN solution 10% NaN3 
PBS Dissolve 5 PBS tablets in 1L ddH2O. Autoclave 
Resolving gel 12% 0.375 M Tris, pH 8.8, 0.1% SDS, 12% Polyacrylamide, 0.1% APS, 0.04% TEMED 
RIPA buffer 50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-
100, 0.1% SDS and 0.5% Sodium deoxycholate 
supplemented with fresh 1X 
protease/phosphatase inhibitor 
Running buffer 5X 125 mM Tris Base, .96 M Glycine, .5% SDS 
SDS loading buffer 62.5 mM Tris, pH 6.8, 50 % (v/v) Glycerol, 12 % 
(w/v) SDS, 0.06 % (w/v) Bromophenol blue. Add 
5% 2- Mercaptoetanol freshly prior to use 
Stacking gel 4% 62.5 mM Tris pH 6.8, 0.1% SDS, 5% Polyacrylamide, 0.1% APS, 0.1% TEMED 
TBST 10X 200 mM Tris, 1.5M NaCl, 1% Tween 20, pH 7.4 
Transfer buffer 10X 250 mM Tris, 1.92 M Glycine. 1X dilution includes 
20%(v/v) Methanol 
Whole-cell extraction buffer 1.5% N-dodecylmaltoside in PBS supplemented 




2.1.4 Cell culture materials 
The following cell culture materials were used during this thesis 
Table 5. Cell culture materials 
 
2.1.5 Cell lines  
HeLa cells used for the experiments in this study were obtained from ATCC. HEK293T cells, 
obtained from Prof. Katschinki’s Lab, were used as packaging cells for the generation of stable 
knock downs of CTSB, UQCRC1, and GAA. Primary mouse embryonic fibroblasts were prepared 
from Gaa KO and Ndufs4 KO mice, respectively, following the procedure previously described 
(Murdoch et al., 2016). Lamp2 KO MEFs were obtained from Prof. Saftig´s Lab. CTSB and CTSL 
MEFs were a kind gift from Prof. Reinheckel´s Lab, and AMPK MEFs were obtained from the 
Viollet´s Lab. 
In the case of the primary mouse embryonic fibroblasts, the cells were prepared from Gaa KO 
and Ndufs4 KO mice ( and their corresponding wild-type (WT) littermates), respectively, following 
the procedure previously described (Murdoch et al., 2016) 
 
Product Supplier Catalog number 
60 x 20 mm TC dish CytoOne CC7682-3354 
100 x 20 mm TC dish CytoOne CC7682-3394 
150 x 20 mm TC dish CytoOne CC7682-3617 
6-well TC plate CytoOne CC7682-7506 
96-well TC plate CytoOne CC7682-7596 
Cell scraper StarLab CC7600-0202 
Countess cell counting 
chamber slides Invitrogen C10283 
Cryogenic vial 2 mL Fisher Brand 1050026 
Filter syringe 0.22 0 Rotilabo 
CME Carl Roth SE2M35I07 






Transfections were done with the following shRNA plasmids  
Table 6. Plasmids used in this thesis 
Plasmid Supplier Catalog number 
Scrambled negative control Integrated DNA Technologies 51-01-19-09 
shRNA-human GAA GE Dharmacon RHS3979-9616754 
shRNA-human UQCRC1 GE Dharmacon RHS3979-200800674 
shRNA-human NDUFS3 GE Dharmacon RHS3979-201765752 





The sequence of the primers used for qPCR was found in Primer Bank repository from Harvard 
Medical School and bought from Integrated DNA Technologies. The primers are listed below. 
Table 7. Human primers 
Primer  Sequence Forward Sequence Reverse 
ACAT2 CTTTAGCACGGATAGTTTCCTGC GCTGCAAAGGCTTCATTGATTTC 
DHCR7 GCTGCAAAATCGCAACCCAA GCTCGCCAGTGAAAACCAGT 
GAPDH GGAGTCAACGGATTTGGTCG GACAAGCTTCCCGTTCTCAG 
HMGCR TGATTGACCTTTCCAGAGCAAG CTAAAATTGCCATTCCACGAGC 
HMGCS1 GATGTGGGAATTGTTGCCCTT ATTGTCTCTGTTCCAACTTCCAG 
HPRT ACCAGTCAACAGGGGACATAA CTTCGTGGGGTCCTTTTCACC 
MVK CATGGCAAGGTAGCACTG GATACCAATGTTGGGTAAGCTGA 
PMVK CCTTTCGGAAGGACATGATCC TCTCCGTGTGTCACTCACCA 
RPL7 AAGATCAAGCGCCTGAGAAAG TGCAGGTACATAGAAGTTGCC 




Table 8. Mouse primers 
Primer  Sequence Forward Sequence Reverse 
ACAT2 CCCGTGGTCATCGTCTCAG GGACAGGGCACCATTGAAGG 
DHCR7 AGGCTGGATCTCAAGGACAAT GCCAGACTAGCATGGCCTG 
GAPDH TGTGTCCGTCGTTCTGA CCTGCTTCACCACCTTCTTGA 
HMGCR TGTTCACCGGCAACAACAAGA CCGCGTTATCGTCAGGATGA 
HMGCS1 CGGATCGTGAAGACATCAACTC CGCCCAATGCAATCATAGGAA 
HPRT CCTCCTCAGACCGCTTTTT AACCTGGTTCATCATCGCTAA 
MVK GGTGTGGTCGGAACTTCCC CCTTGAGCGGGTTGGAGAC 
PMVK AAAATCCGGGAAGGACTTCGT AGAGCACAGATGTTACCTCCA 
RPL7 CTGCTGGGCCAAAAACTCTCA CCTTCAACTCTGCGAAATTCCTT 
RPS12 CTCATCCACGATGGCCTAGC ACATGGGCTCATCACAGTTGG 
SCAP CCGAGCATTCCAACTGGTG CCATGTTCGGGAAGTAGGCT 







The list of antibodies used during this thesis are listed below 
























Antibody Supplier Catalog number Dilution 
ACC Cell signaling 3676 1:1000 
ACC pSer79 Cell signaling 3661 1:1000 
ATG5 Cell signaling 12994 1:1000 
P70S6K1 Cell signaling 2708 1:1000 
P70S6K1 
pThr389 Cell signaling 9234 1:1000 
TSC2 Cell signaling 4308 1:1000 
pTSC2 Cell signaling 5584 1:1000 
GAPDH Sigma Aldrich G9545 1:10000 
HPRT Abcam ab10479 1:4000 
LC3B (D11) Cell Signaling 3868 1:2000 
S6 Cell signaling 2217 1:2000 
S6 pSer235/236 Cell signaling 4858 1:2000 
UQCRC1 Abcam ab110252 1:1000 
SREBP1 Novus NB100-2215 1:500 
SREBP2 Abcam ab30682 1:500 
HMGCR Abcam ab174830 1:1000 
HMGCR Ser872 BIOSS bs4063R 1:1000 
AMPKα Cell signaling 5832 1:1000 
pAMPKα Cell signaling 2535S 1:1000 
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Table 10. Secondary antibodies for immunoblotting 
Antibody Supplier Code 
Goat anti-mouse IgG Dianova 115-035-146 
Goat anti-rabbit IgG Dianova 115-035-144 
 
2.1.9 Instruments 
The instruments used for this thesis are listed below 
Table 11. List of instruments and equipment 
Instrument Manufacturer 
Ace Block Digital Dry Bath Labnet 
Bio-Rad Power Pack HC Mini-Protean Tetra 
System Bio-Rad 
Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Centrifuge Allegra X-15R Beckman Coulter 
Countess C10281 Invitrogen 
Cryogrider tool kit 230V OPS Diagnostics 
Gene Quant 1300 GE Healthcare 
Hood Herasafe Thermo Scientific 
Incubator Heracell 150i Thermo Scientific 
Leica CM 1850 Cryostat Leica Biosystems 
Multichannel pipette Eppendorf Research 
Nanodrop 2000C Peqlab 
pH meter pH7110 WTW Inolab 
Pipette gun accu-jet pro BrandTech Scientific Inc. 
Pipettes Eppendorf Research 
Potter S (Dounce homogenizer) Sartorius 
Precision balance Explorer OHAUS 
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Quant Studio 6 Flex Life Technologies 
Revolver wheel Labnet 
Scanner Epson Perfection V850 Pro Epson 
SE600 Ruby system GE Healthcare 
SYNERGYM1 microplate reader BioTek 
Thermocycler UNO II Biometra 
Vortex RS-VA10 Phoenix Instrument 
 
2.1.10 Software 
The programs used during this project are listed below: 
Adobe Illustrator CS6, Adobe Systems Inc., USA 
GraphPad Prism 7, GraphPad Software Inc., USA 
ImageJ, NIH, USA 
Ingenuity Pathway Analysis, QIAGEN, USA 
Mendeley, Mendeley Ltd, UK 
Microsoft Office, Microsoft Corporation, USA 






2.2.1 Cell Culture 
2.2.1.1 Procedure for plating cells 
All cells were grown in Dulbecco's Modified Eagle Medium high glucose medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (P/S), hereafter 
called normal medium, in a monolayer cultured at 37°C and 5% CO2. Only UQCRC1 KD HeLa cells 
and their corresponding scrambled controls were grown in normal medium supplemented with 
1 mM pyruvate. Prior use, all media, and solutions used for cell culture were either autoclaved 
or filtered. Cells were counted using a cell counter, and they were about 95% confluent when 
collected for experiments. 24h, before realizing the experiment, cells were plated, and the 
seeding cell number was modified according to the area of the plate. The most used seeding 
densities during this project were approximate:  
Size of the cell culture plate Seeding density 
15 cm 3.0 x 106 cells 
10 cm 1.25 x 106 cells 
6 cm 3.0 x 105 cells 
6-well plate 1.5 x 105 cells 
96-well plate 1.5 x 104 cells 
 
2.2.1.2 Collection of cells 
The cells were collected for the preparation of the whole-cell lysates for nucleic acid, protein, 
and lipid extraction by removing the growth medium and washing one time in cold PBS. For this 
process, the medium was replaced with 5 ml cold PBS, and cells were scraped on ice. After 
obtaining the suspension of cells in PBS, the suspension was divided into two: 500 µl were 
collected in an Eppendorf tube (this fraction was used for nucleic acid isolation), and the rest was 
collected in a falcon latter used for protein extraction or lipid extraction. The cell suspensions 
were pelleted at 3600 rpm, 4°C for 5 minutes. The supernatant was discarded, and the pellets 
were used immediately for the experiments or stored at -20°C for later use. 
2.2.1.3 Mitochondrial isolation from cultured cells 
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Mitochondria were isolated from cultured cells according to a previously described protocol 
(Wieckowski et al., 2015). Cells were collected by incubation for 5 minutes with trypsin, and 
trypsinization was halted by the addition of fresh normal medium. The cell suspension was then 
centrifuged for 5 minutes at 600 g, 4°C. The pellet obtained from the centrifugation was washed 
with PBS and centrifuged again as previously described. The supernatant obtained from the 
centrifugation was discarded, the pellet was resuspended in homogenization buffer 
(mitochondrial isolation buffer, previously described, supplemented with protease and 
phosphatase inhibitors, 1 mM DTT, and 100 µM PMSF) and incubated for 15 minutes on ice. To 
avoid degradation of the sample, further steps of the isolation were carried out at 4°C.  
After the incubation on ice, the cells were homogenized using a Potter-Evehjem homogenizer 
with a Teflon pestle for at least 50 strokes. The homogenate was transferred to a new 
polypropylene centrifuge tube and centrifuged for 5 minutes at 600 g, 4°C. The obtained pellet 
was discarded (unbroken cells and nuclei) and the supernatant was collected into a new tube for 
another centrifugation step of 5 minutes at 600 g, 4°C. Again, the pellet was discarded, and the 
new supernatant was centrifuged 10 minutes at 7000 g, 4°C. The mitochondrial fraction(pellet), 
was resuspended in 5-10 ml homogenization buffer (according to the size of the pellet) and 
centrifugated again for 10 minutes at 7000 g, 4°C; this step was repeated twice. Finally, the pellet 
was resuspended in 200 µL of homogenization buffer. 
2.2.1.4 Pharmacological treatments 
Before treatment, HeLa cell and mouse embryonic fibroblast (MEF) cell were seeded according 
to de densities previously described. The concentrations used (unless stated otherwise) were: 
250 µM Rotenone, 10 µM U18666A, and 250 nM Torin. For the experiment with supplementation 
of 1% v/w (2-Hydroxypropyl)-β-cyclodextrin (HPCD), the compound was previously dissolved in 
normal medium and filtered to avoid contamination. Before the addition of the drug to the 
medium, cells were washed with PBS, and the normal medium was replaced with medium 
supplemented with the corresponding drug or its control. 
2.2.1.5 Generation of stable HeLa KDs 
The generation of stable knockdown in HeLa cells were generated using shRNA following the 
protocol described by (Fernandez-Mosquera et al., 2019). Briefly, lentiviral stable knock downs 
were generated by transfecting HEK293T packaging cells with an optimized mix of packaging 
plasmids and either of GAA, CTSB, and UQCRC1 shRNAs targeting five different regions of each 
coding gene or scrambled non-targeting negative control shRNA using Lipofectamine 2000. After 
that, lentiviral vectors were concentrated using the Lenti-X concentrator. HeLa cells were 
transduced with lentiviral particles supplemented with 8ug/ml Polybrene. For the selection of 
the knockdowns, puromycin was used. Finally, the efficiency of the knockdown was confirmed 




2.2.2 Mice handling 
2.2.2.1 Mouse lines 
The mouse lines used for the experiments, both obtained from Jackson´s Lab USA, were Gaa KO 
mice and Ndufs4 KO mice, and their wild-type controls. All the procedures concerning the animals 
were reviewed and approved by the Institutional Animal Care and Use Committee of the 
University Medical Center Göttingen. 
2.2.2.2 Mouse tissue extraction 
Before euthanizing mice by cervical dislocation, the mice were anesthetized with isoflurane. For 
the extraction of tissue, the body of the animal was placed in a petri dish and sprayed with 70% 
ethanol. Once the abdomen was opened, a small piece of the liver was cut and deposited in an 
Eppendorf tube. For heart extraction, a similar procedure was followed. The heart was rinsed in 
PBS several times to remove the blood and placed in an Eppendorf tube. Skeletal muscle 
(quadriceps) was collected from the mice after removing the skin and placed in an Eppendorf 
tube. Immediately after each sample was collected, they were placed in a container with liquid 
nitrogen for a few seconds. After the period in liquid nitrogen, samples were stored at -80°C. 
Before usage for other applications, tissues were powdered by grinding under liquid nitrogen 
using a cryogrinder toolkit. The powder was split into several tubes for further experiments and 
stored at -80°C. 
 
2.2.3 Molecular biology 
2.2.3.1 RNA isolation 
2.2.3.1.1 Mouse tissue 
For the isolating RNA from tissues, TRI reagent (Sigma) was used. 1ml of TRI reagent was added 
to the powder of the tissues (previously generated) in a 1.5 ml Eppendorf tube to form a 
homogenate. This homogenate was incubated for 5 minutes at room temperature. After the 
incubation, 200 µL of chloroform was added. To mix the sample, the tubes were shaken 
vigorously by hand for 15 seconds and incubated at for 2–3 minutes at RT. The samples were 
then centrifuged at 12000 x g for 15 minutes at 4°C. Approximately 500 µL of the aqueous phase 
was carefully removed and placed in new RNAse-free 1.5mL Eppendorf tubes. For the RNA 
precipitation isopropanol was used, in this case, the precipitation was done by adding 500 µL of 
isopropanol and incubating at room temperature for 10 minutes. After 10 minutes, the samples 
were centrifuged at 12000 g for 10 minutes at 4°C.  The RNA pellet was washed in 1 mL 75% 
ethanol, vortexed briefly and centrifuged at 7500 g for 5 minutes at 4°C. The supernatant was 
completely removed and the RNA pellet was dried for 5–10 minutes at RT. Finally, the pellet was 
resuspended in 300 μL of RNAse-free water. The RNA concentration was determined and the 
RNA was either used immediately or frozen at -80°C. 
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2.2.3.1.2 Cultured Cells  
For RNA isolation from cells, the commercial kit CRYSTAL RNA Mini Kit (BIOLAB) was used. The 
procedure was done according to the manufacturer’s specification. Cell pellets were incubated 
with 400 μL of Lysis Solution RL (supplemented with 1% 2-Mercaptoethanol (β-SH)). The initial 
incubation period was 2 minutes, after that the pellet was resuspended and incubated again for 
3 minutes at room temperature. After the incubation, the suspension was transferred into a Spin 
Filter D column set ina 2 mL Receiver Tubes and centrifuged for 2 minutes at 10000 g. After the 
centrifugation, the Spin Filter D was discarded and 400 μL of 70 % ethanol was added to the flow-
through. Once the ethanol and the sample were mixed by pipetting, they were transferred to 
Spin Filter R in a new Receiver Tubes 2 mL. The Spin Filter R was centrifuged for 2 minutes at 
10000 x g. After the centrifugation, the Spin Filter R was placed into a new tube. In this new tube, 
500 μL of Washing Solution HS was added to the Spin Filter, and the column was centrifuged for 
1 minute at 10000 g. For the last wash, 700 µL of Washing Solution LS was added to the Spin Filter 
R and centrifuged as before for 1 minute.  To dry the membrane of the Spin Filter R, the column 
was placed into a clean 2mL receiver tube and centrifuged for 2 minutes at 10000 g. Finally, for 
the elution of RNA, the column was incubated 1 minute with RNAase-free water and centrifuged 
for 1 minute at 6000 x g to collect the RNA.  
2.2.3.2 Determination of nucleic acid concentrations 
To measure RNA concentration, The Nanodrop (PeqLab) spectrophotometer was used. For this 
purpose, 1 μL of blank (nuclease-free water) or sample was applied to the Nanodrop. The 
Nanodrop measured the sample concentration, and absorbances at 260 nm and 280 nm to 
control the quality of nucleic acids. The results of RNA concentration were then exported as 
Microsoft Excel files.  
2.2.3.3 Synthesis of cDNA  
Complementary DNA (cDNA) was employed for the experiments of gene expression experiments. 
the isolated RNA (isolation previously described) was reverse transcribed using iScript cDNA 
synthesis kit. All the reagents of the kit and the sample were kept on ice during the whole process. 
The reaction in each PCR tube was made of the following components: 1 µg of RNA, 4 µL of 5X 
iScript reaction mix, 1 µL of iScript reverse transcriptase, and nuclease-free water to reach the 
final volume of 20 µL. Once the PCR tubes was vortexed, they were centrifuged shortly. Finally, 
the tubes were incubated in a thermocycler with the following protocol: priming for 5 minutes at 
25°C, reverse transcription for 30 minutes at 46 ° C, reverse transcriptase inactivation for 1 
minute at 95°C, and the last step of holding at 4°C. The synthesized cDNA stored at -20°C until it 
was used in qPCR. 
2.2.3.4 Quantitative-PCR (qPCR)  
Real-time PCR was employed to measure the levels of transcripts from the previously synthesized 
cDNA. Real-time PCR was performed in at least four technical replicates using Luna ® Universal 
61 
 
qPCR Master Mix. The final volume of the reaction was 8 µL per well in a 384-well plate, which 
consisted of 3.6 µL Luna ® Universal qPCR Master Mix, 0.4μl of primers ( 0.2µL of forward and  
0.2µL of reverse) for each gene, and 4 μl of diluted cDNA template (the dilution used was 1:50). 
The plate was sealed with adhesive seal, shortly centrifuged for 1 minute and incubated in the 
QuantStudio™ 6 Flex Real-Time PCR system (Life Technologies). The following protocol was used 
for qPCR: polymerase activation for 30 seconds at 95°C, amplification for 40 cycles with steps of 
denaturation for 3 seconds at 95°C, annealing for 30 seconds at 56°C, and extension for 30 
seconds at 60°C. Melt-curve analyses were done at steps of 85°C for 15 seconds, 52°C for 30 
seconds and 95°C for 15 seconds. Data obtained were analyzed with QuantStudio™ Real-Time 
PCR Software and exported as Microsoft Excel files for further analyses using the ΔΔCT method. 
 
2.2.4 Biochemical experiments  
2.2.4.1 Preparation of protein samples from mouse 
2.2.4.1.1 Protein extraction from tissue powder 
For the preparation of tissue lysates, the tissue powder previously obtained was resuspended in 
500 μL of RIPA buffer supplemented with protease and phosphatase inhibitor to avoid protein 
degradation. The tube was vortexed briefly, and the tissue was lysed by rotation at 4°C for 1 hour. 
Tissue homogenate were centrifuged at 16000 rpm, 4°C for 20 minutes. The resulting 
supernatant (tissue lysate) was collected into a new 1.5 mL Eppendorf tube. The protein 
concentration of the tissue lysate was determined by the Pierce Assay. Lysates were used for 
further experiments or stored at -80°C.  
2.2.4.1.2 Protein concentration determination of Tissue lysates 
To determine the protein concentration of tissue lysates, the Pierce BCA Protein Assay Kit (Bio-
Rad) was used, the manufacturer’s instructions were followed for the protein quantification. The 
protein concentration of the lysates was determined in duplicates and before the quantification 
samples were diluted in a proportion of 1:40. For the quantification, a calibration curve was made 
of BSA standard. 50 μL of diluted samples were mixed with 1mL Pierce BCA working solution 
(reagents A and B, 50:1) in a glass tube and vortexed briefly. The tubes were incubated at 37°C 
for 30 minutes in the dark and transferred into plastic cuvettes. The absorbance was measured 
at 562 nm using a GeneQuant 1300 spectrophotometer. Finally, the protein concentration of the 
lysates was determined based on the standard calibration curve using Microsoft Excel software. 
2.2.4.2 Preparation of proteins from cells 
2.2.4.2.1 Protein extraction from pellets 
The pellets obtained from cells, were placed on ice and about 50 to 100 μL of whole cell extraction 
buffer (see Table 3 above) was added depending on the pellet size. The suspension was 
transferred to 1.5ml Eppendorf tubes and lysed by rotation at 4°C for 30 minutes. The resulting 
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cell lysate was then centrifuged at 16000 rpm, 4°C for 20 minutes. The supernatant (containing 
the whole cell lysate) was collected into new 1.5mL Eppendorf tubes. The protein concentration 
was determined by the Bradford Assay. Lysates were either used immediately or stored at -20°C. 
2.2.4.2.2 Protein concentration determination of cell lysates  
Protein concentration from cells was determined using Protein Assay Dye Reagent Concentrate 
(Bio-Rad). The procedure used was according to the manufacturer’s instructions. For standard 
curve defined concentrations of BSA was used. In order to measure the protein concentration (at 
least duplicates were measured), 1 µL of the sample was diluted in 800 μL of ddH2O. 200 μL of 
protein assay dye reagent was added and the tubes were briefly mixed by vortexing and 
incubated in the dark for 5 minutes at room temperature (RT). After the incubation period, the 
mix was transferred into plastic cuvettes and the absorbance was measured at 595 nm using a 
GeneQuant 1300 spectrophotometer. The protein concentration was calculated based on the 
standard calibration curve using Microsoft Excel 2013 
2.2.4.3 SDS-Polyacrylamide gel electrophoresis  
2.2.4.3.1 Preparation of gels 
In order to separate denatured proteins according to their molecular weight, a polyacrylamide 
gel was prepared. The acrylamide gels were prepared using the Bio-Rad Gel preparation system 
and 40% acrylamide solution. In all experiments, the used concentration of the resolving gel was 
12% (composition previously described), and the thickness of the gel was 1mm. Initially, the 
resolving gel was added between two glasses and covered with isopropanol. After the 
polymerization, the isopropanol was discarded from the gel. The gel was rinsed with ddH2O. Once 
the water was drained, the 4% stacking gel (see Table 3 above) was added on the top of the 
resolving gel. Immediately after the gel was poured, the 10-well comb was inserted into the 
stacking gel. After the polymerization of the gels, the gels were placed in a container filled with 
1 X running buffer for storage at 4°C or used immediately.  
2.2.4.3.2 Electrophoresis 
The Mini-Protean Tetra System (Bio-Rad) was used to perform the SDS-PAGE.  The gels were 
placed in the running apparatus without the combs, and the container was filled with 1X running 
buffer. The samples were prepared by mixing 6x SDS loading buffer and a determined protein 
concentration of 30 µg. Once the sample was mixed with the loading buffer, the mix was boiled 
at 95°C for 5 minutes. In all the wells of the gel, the same amount of protein was loaded. The 
electrophoresis was run at a constant voltage. Initially, the voltage was set at 100 V. When the 
samples entered the resolving gel, the voltage was changed to 180 V. As a standard of molecular 
weight, the Page Ruler plus Prestained was used.  
 
2.2.4.4 Western blotting  
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Western blot was carried according to the protocols described by (Fernandez-Mosquera et al., 
2019). Polyvinylidene fluoride membrane (PVDF) were activated for 15 sec in methanol, washed 
with ddH2O for 1 minute, and equilibrated for 5 min in transfer buffer prior to use. After the run, 
the gels were taken out of the glass plate, the stacking gel was cut out, and gels were equilibrated 
in cold transfer buffer. Before use, the transfer sponges and sheets of Whatman paper were 
previously soaked for some time in transfer buffer. Using a tank transfer system, the transfer 
sandwich was assembled on a plastic transfer cassette soaked in transfer buffer to avoid trapping 
air bubbles. In between two sponges, and two sheets of Whatman paper on each side, the 
activated membrane was placed on top of the gel. A rolling tool was used throughout to 
completely remove air bubbles. The assembled transfer cassetes with the sandwich were placed 
in the transfer chamber and filled with transfer buffer. Finally, a cold ice pack was placed in the 
tank to avoid excessive heating. The electrophoresis was done at constant voltage 100V for 90 
minutes at 4oC. 
2.2.4.5 Immunodetection  
Following transference, the membranes were blocked in 5% Milk in TBST with gentle shaking for 
1 hour at RT. After the blocking, membranes were washed three times in TBST for 10 minutes 
and incubated with primary antibodies overnight at 4 °C. After the incubation with the primary 
antibody, membranes were washed three times with TBST for 10 minutes. After the washes, the 
membranes were incubated for 1h at room temperature with the corresponding HRP-conjugated 
secondary antibodies. The secondary antibody was prepared in the in blocking buffer. The 
secondary antibody was discarded, and the membranes were washed three more times in TBST 
for 10 minutes. Once done with the washes, the chemiluminescence was detected by incubating 
membranes in Luminata Western HRP substrate during 3 minutes, and developing signals on 
medical X-ray films using the AGFA Curix 60 processor. For quantification, the films were scanned, 
and quantification of the bands was done using ImageJ software. 
 
2.2.5 Cholesterol content measurement 
2.2.5.1 Free cholesterol content measurement by Filipin 
Cells were seeded in a 96-well plate (seeding density previously described) the day before the 
experiment. Initially, the cells were washed three times for 10 minutes with ice-cold PBS. Once 
the washes were done, the filipin was added (concentration of 0.1 mg/mL dissolved in PBS) to 
each well and incubated during 30 minutes in dark conditions with mild shaking. After the 
incubation, cells were washed three times with ice-cold PBS. The measurement of the fluorescent 
intensity was done in a microplate reader, and the content of cholesterol was normalized to 
protein content using Pierce BCA microassay. 
2.2.5.2 Protein concentration determination using Pierce BCA microassay 
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Once the cholesterol content was measured with filipin in 96-well plates, the protein 
concentration per well of samples was quantified for normalization of the cholesterol content. 
For this purpose, immediately after the measurement with filipin, PBS was removed, and the cells 
were lysed with 125 μL of ddH2O for 60 minutes with mild shaking. After the lysis, protein 
concentrations were determined using the Pierce BCA Protein Assay kit. To measure the protein 
concentration, 100 μl of double concentrated Pierce BCA working reagent (reagents A and B, 
25:1) was added to each well-containing sample and blank. Samples were mixed and incubated 
for 30 minutes at 37 °C. Finally, the absorbance was measured at 562 nm in a microplate reader. 
The protein concentration was calculated from a standard curve made from albumin standards. 
2.2.5.3 Lipids extraction 
The lipid extraction was done according to the extraction procedure described by Folch and 
colleagues (Folch et al., 1957). The extraction of lipids was done from harvested cells and isolated 
mitochondrial fractions. In the case of extraction from harvested cells, they were collected with 
5 mL PBS (50 µL of the sample was kept for protein quantification by Bradford assay) and after 
centrifugation for 5 minutes at 3600 rpm, 4°C. The obtained pellet or 100 µL of the isolated 
mitochondrial fraction were resuspended in 250 µL of a mix made of chloroform/methanol (2/1). 
Immediately, the cell suspension was transferred to a glass tube and vortexed briefly. The solvent 
was washed with 0.2 volumes of ddH2O, in this case, 50 µL was used. After vortexing for a few 
seconds, the suspension was centrifuged for 5 minutes at 2000 rpm to separate the two phases. 
The lower chloroform phase contains the lipids, and this phase was collected, taking 100 µL 
directly from the bottom of the tube. The chloroform was evaporated under vacuum for at least 
30 minutes and the lipids resuspended in “Reaction Buffer” provided from Amplex® Red 
Cholesterol Assay Kit. 
2.2.5.4 Cholesterol quantification using Amplex® Red Cholesterol Assay Kit 
Total cholesterol content was determined using the Amplex® Red Cholesterol Assay Kit, the 
procedure according to the manufacturer specifications was followed. The experiments were 
done in a 96-well plate and with at least technical triplicates. To prepare the samples, to each 
well 5 µL of the previously extracted lipid samples was added to 45 µL of Reaction Buffer. To start 
the reaction, 50 µL of Amplex Red working solution was added (working solution contains 300 
µM Amplex ® Red reagent, 2 U/mL HRP,2 U/mL cholesterol oxidase, and 0.2 U/mL cholesterol 
esterase) and the microplate was incubated during 30 minutes protected from the light. The 
fluorescence corresponding to cholesterol content was measured at excitation and emission 
wavelengths of 530nm and 590nm respectively using, a microplate reader. The cholesterol 
content was calculated from a standard curve made from cholesterol and then normalized to the 
protein concentration of each sample. 
2.2.6 Statistical analyses and graphs 
For statistical analysis, Microsoft Excel 2016 was used. Graphs were plotted with GraphPad Prism 
version 7. In all cases, the graphs show mean normalized to loading control (western blot) or 
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control gene (qPCR). The mean of controls was always fixed to 1. The error bars correspond to 
standard deviation or standard error of the mean for at least biological triplicates as stated in the 
legends for each figure. The differences between the means were determined by the Student’s 
t-test for two-parameter comparisons. These differences were displayed in the graphs as * p < 
0.05; **p < 0.01; ***p < 0.001. 
2.2.7 Bioinformatic analysis 
RNA sequencing was performed following the protocol described by Murdoch et al., 2016. The 
pathway analysis was done as described in Raimundo et al., 2012. Briefly, RNA samples were 
purified from NDUFS3, UQCRC1, GAA, and CTSB knock down HeLa cell lines along with scrambled 
controls using CRYSTAL RNA mini kit. The RNA concentration and quality were determined by 
Nanodrop. Samples were sequenced on HiSeq 2000 (Illumina) with support from the 
Transcriptome and Genome Analysis Laboratory (TAL) of the University of Goettingen Medical 
Center (UMG). 
Read alignment and quality assessment, as well as normalization, were done using Strand NGS 
software. Differentially expressed genes in the respective knock downs relative to the scrambled 
control with adjusted p-value less than 0.05 were imported into the Ingenuity Pathway Analysis 
(IPA) software for functional enrichment analysis. In the result section, the top ten significantly 






3.1 Generation of the stable knock downs
Initially, we generated stable knock downs (KDs) of our genes of interest using short hairpin RNAs 
(shRNAs) delivered by lentiviral vectors to HeLa cells. We selected two mitochondrial and two 
lysosomal genes. In the case of the mitochondrial genes, we selected NADH:Ubiquinone 
Oxidoreductase Core Subunit S3 (NDUFS3, a subunit of the complex I of the respiratory chain) 
and Ubiquinol-Cytochrome C Reductase Core Protein I (UQCRC1, a subunit of the complex III of 
the respiratory chain). From the lysosomal genes, we selected Cathepsin B (CTSB) and Acid Alpha 
Glucosidase (GAA) both involved in the macromolecules in the lysosome. In all cases, the protein 
selected has been studied as different diseases models. For the mitochondrial models: NDUFS3 
deficient cells are a mitochondrial complex I deficiency model (Haack et al., 2012), UQCRC1 is 
studied as a model of chronic mitochondrial dysfunction (Fernandez-Mosquera et al., 2019). In 
the case of the lysosomal models: cells lacking GAA are Pompe´s disease model (Parenti et al., 
2015), and CTSB is enzymes with huge importance in cancer (Olson and Joyce, 2015). KDs of these 
four genes were generated as described above, thus creating two model cell lines of 
mitochondrial dysfunction, and two of lysosomal dysfunction.  
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Figure 12. Transcriptome data analyses. Volcano plots corresponding to NDUFS3 KD (A), UQCRC1 KD (B), GAA KD 
(C) and CTSB KD (D). Downregulated genes are shown in blue, upregulated genes in red and unchanged genes in 
black. Differentially expressed genes were identified by a cut-off of adjusted p-value < 0.01. 
We tested five different shRNAs for each gene and determined the two most efficient ones for 
each target. Once we confirmed the individual KDs at both transcript and protein levels, RNA was 
extracted from all the cell lines (UQRCR1 KD, NDUFS3 KD, CTSB KD, and GAA KD) and a control 
cell (scrambled shRNA). Next, the RNA was sent to the next generation sequencing (NGS) facility 
available in Göttingen for RNA sequencing (RNA-Seq). The data that we obtained from the RNA-
Seq was analyzed in the lab using the most recent bioinformatic tools available comparing the 
expression levels of the genes in each stable KD with the control cell line., in this way we obtained 





Figure 13. Top 10 canonical pathways affected in each model. Top panel: Canonical pathways altered in lysosomal 
KDs. Bottom panel: Canonical pathways impaired in mitochondrial KDs. Superpathway of cholesterol biosynthesis is 
marked in red. Associated P values were determined according to analysis in the database for annotation, 
visualization, and integrated discovery (Fisher exact P-value). 
 
The analyzed data showed KD-specific differentially expressed genes (Fig. 12), which we fed 
through our multi-dimensional genomics analyses pipeline. One of the analyzed dimensions is 
the pathways enriched in our differentially regulated gene list. The top pathways perturbed by 
all the KDs were lipid biosynthetic pathways, particularly the cholesterol pathway (Fig. 13). 
Cholesterol is an essential lipid in the cell membrane, controlling and contributing to its fluidity 
(Goldstein et al., 2006). 
 
Figure 14. Transcriptome data analyses. The selected transcripts, represented in the heatmaps, were obtained from 
the canonical pathway of cholesterol biosynthesis significantly change in the pathway analysis. Heatmaps, showing 
reduced transcript levels of enzymes necessaries for the cholesterol biosynthesis in UQCRC1 KD (A) and increased in 
the transcript levels of cholesterol biosynthesis in GAA and CTSB KDs (B). 
The KD of one key mitochondrial protein, UQCRC1 KD resulted in a downregulation of 40% of the 
transcripts involved in the cholesterol biosynthesis pathway (Fig. 14A). On the other hand, 
lysosomal perturbations (CTSB and GAA KDs) triggered an increase of approximately 45% in the 
transcript levels of the genes from the cholesterol biosynthesis pathway. This increase suggests 
an activation of the cholesterol biosynthesis pathway (Fig. 14B). 
Next, we aimed to validate using quantitative real-time PCR (qPCR) the transcript levels for our 
genes of interest.  
3.2 Validation of the data obtained from the analyses of the RNA Seq results 
3.2.1 Mitochondrial dysfunction model 
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We validated by qPCR the results obtained from the transcriptomic analyses by evaluating the 
expression levels of the key genes of the enzymes involved in the cholesterol biosynthesis 
pathway. The main enzymes selected were Acetoacetyl-CoA Synthetase (ACAT2), HMG-CoA 
Synthase (HMGCS1), HMG-CoA Reductase (HMGCR), Mevalonate Kinase (MVK), 
Phosphomevalonate Kinase (PMVK) and 7-Dehydrocholesterol Reductase (DHCR7). 
 
Figure 15. Validation of RNA Seq results in HeLa UQCRC 1 KD. Expression levels of the main enzymes involved in the 
cholesterol biosynthesis pathway. The transcript levels were determined by the ΔΔCT method using RPL7 (Ribosomal 
Protein L7) as a reference gene; the plotted value corresponds to the relative expression of the gene (fold change). 
Samples were centered to one by normalization of the gene expression of the experimental sample to its 
corresponding control, in this case, scrambled. Graphs show mean ± SD; p <0.05 (*), p < 0.01 (**); Student’s t-test; 
SD: standard deviation. n=5. 
As expected, at transcript levels of all the enzymes previously mentioned except ACAT2 were at 
least between 20-30% significant decreased. The results we obtained from UQCRC1 KDs were 
consistent with the outcomes of the NGS data. Indeed, the cholesterol biosynthesis pathway was 
downregulated in the HeLa UQCRC1 KD (Fig. 15). 
3.2.2 Models of lysosomal dysfunction 
A similar strategy was employed in the case of the models of lysosomal dysfunction that we 




Figure 16. Validation of RNA Seq results in HeLa CTSB and GAA KDs. Expression levels of the principal enzymes of 
the cholesterol biosynthesis pathway. The transcript levels were determined by the ΔΔCT method using RPL7 
(Ribosomal Protein L7) as a reference gene; the plotted value corresponds to the relative expression of the gene 
(fold change). Samples were centered to one by normalization of the gene expression of the experimental sample 
to its corresponding control, in this case, scrambled. Graphs show mean ± SD; p <0.05 (*), p < 0.01 (**), p < 
0.001(***); Student’s t-test; SD: standard deviation. n= 4. 
Similarly, the qPCR transcript level measurement of the cholesterol biosynthesis pathway in CTSB 
and GAA KDs were consistent with NGS data of the models of lysosomal malfunction. The activity 
of the cholesterol biosynthesis pathway was affected in this case (Fig. 16) showing an average of 
2 times fold increase in the expression levels of ACAT2 and PMVK; and an increase of between 2 
to 3 times fold in HMGCS1, HMGCR, MVK, and DHCR7. Altogether, points towards upregulation 
of the pathway.  
Based on the described results, we conclude that the relevant transcript levels are consistent 
between RNA-Seq and qPCR measurement. Therefore, we next aimed to unravel the mechanistic 
steps of the observed phenotypes.  
3.3 Regulation of cholesterol pathway by SREBP1 
We next measured the protein levels, one of the main transcription factors for the synthesis of 
the lipid, sterol regulatory binding protein 1 (SREBP1) associated with the activation of the 
cholesterol biosynthesis pathway. When the levels of active SREBP1 are increased, SREBP1 acts 
as a transcription factor that translocates to the nucleus activating the cholesterol biosynthesis 
pathway (Shao and Espenshade, 2012). 
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In a cellular model of mitochondrial dysfunction such as UQCRC1 KD, SREBP1 was inactive, as 
measured by WB, (Fig. 17A), in agreement with the downregulation of the pathway. 
 
Figure 17. UQCRC1 KD HeLa decreases the protein levels of active SREBP1. A) UQCRC1 KD HeLa showed a significant 
decrease in the protein levels of SREBP1; in CTSB KD HeLa there was no change observed. B) Quantification of the 
Western blot. For the quantification, two biological replicates were used. Control (scrambled) value was centered at 
1, and the HeLa KDs values were normalized to the control (scrambled). Graph presents mean ± SD; p < 0.01 (**); 
Student’s t-test; SD: standard deviation. 
Simultaneously, we tested if the differential regulation of cholesterol biosynthesis is conserved 
in other cell lines, considering that HeLa cells are cancer cells and have physiology far from that 
of healthy cells in tissues (Hyman and Simons, 2011). We, therefore, introduced mouse 
embryonic fibroblasts (MEFs) since fibroblasts are cells from mesenchymal origin located in 
several tissues and can respond to multiple stimuli (Qiu et al., 2016). 
 
3.4 Cholesterol biosynthesis pathway is downregulated in a mouse model of mitochondrial 
dysfunction 
By employing standard procedures, we have obtained MEFs from the Ndufs4 KO mouse, a mouse 
model of mitochondrial malfunction lacking the NDUFS4 subunit of the respiratory chain complex 





Figure 18. Downregulation of cholesterol synthesis in Ndufs4 KO MEFs. A) Downregulation of the transcript levels 
of the main enzymes involved in the synthesis of cholesterol in Ndufs4 KO MEFs. The transcript levels were 
determined by the ΔΔCT method using RPL7 (Ribosomal Protein L7) as a reference gene; the plotted value 
corresponds to the relative expression of the gene (fold change). Samples were centered to one by normalization of 
the gene expression of the experimental sample to its corresponding control, in this case, WT. B) Western blot of 
SREBP1 and its quantification, showing a decreasing trend in the levels of the protein. For the quantification, two 
technical replicates were used. WT value was centered in one, and the KO value was normalized to the WT. Graphs 
show mean ± SD; p <0.05 (*), p < 0.01 (**), p < 0.001(***); Student’s t-test; SD: standard deviation. n= 5. 
There is a reduction (at least 20%) in the transcript levels of most of the genes from the 
cholesterol biosynthesis pathway (Fig. 18A). The levels of active SREBP1 tends to decrease when 
compared with wild-type cells, indicating that the pathway of biosynthesis of cholesterol displays 




3.5 Cholesterol biosynthesis is upregulated in three independent mouse models of lysosomal 
dysfunction 
To investigate additional models of lysosomal dysfunction, we used three different kinds of MEFs, 
each a knock out for lysosomal proteins: two corresponding cysteine cathepsins (CtsB and CtsL) 
and acid alpha glucosidase (Gaa). 
 
Figure 19. Upregulation of the synthesis of cholesterol Gaa KO MEFs. (A) Upregulation of the levels of the enzymes 
involved in the cholesterol synthesis pathway in Gaa KO MEFs. The transcript levels were determined by the ΔΔCT 
method using RPL7 (Ribosomal Protein L7) as a reference gene; the plotted value corresponds to the relative 
expression of the gene (fold change). Samples were centered to one by normalization of the gene expression of the 
experimental sample to its corresponding control, in this case, WT (B) Western blot and quantification of SREBP1 
active in Gaa KO MEFs, showing a significant increase in the SREBP1 protein levels. For the quantification two 
technical replicates were used. WT value was centered in one, and the KO value was normalized to the WT. Graphs 
show mean ± SEM; p <0.05 (*), p < 0.01 (**), p < 0.001(***); Student’s t-test; SEM: standard error of the mean. n= 
4. 
Confirming our predictions, in MEFs, deletion of necessaries enzymes for the normal function of 
the lysosome such as Gaa, and CtsB and CtsL (Fig. 20) led to an upregulation of genes from the 
synthesis of cholesterol pathway, suggesting pathway activation. In the case of the Gaa KO, we 
observed a strong increase in most of the transcript levels of 4 times fold in the genes from the 
cholesterol biosynthesis pathway (Fig. 19A). Although not as strong as in the Gaa KO MEFs, we 
also observed a significant increase in the cholesterol biosynthetic pathway in CtsB and CtsL KO 
(Fig. 20A) even though the increase of the transcript levels was more in CtsB than in CtsL. 
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Concerning the levels of active SREBP1, we observed a significant increase in its levels in all 
lysosomal dysfunction model in MEF, Gaa KO MEFS (Fig. 19B), and CtsB and CtsL KO MEFs (Fig. 
20B). 
 
Figure 20. Upregulation of the synthesis of cholesterol in two different models of lysosomal dysfunction. (A) 
Upregulation of the levels of the enzymes involved in the cholesterol synthesis pathway in CtsB and CtsL KO MEFs. 
The transcript levels were determined by the ΔΔCT method using RPL7 (Ribosomal Protein L7) as a reference gene; 
the plotted value corresponds to the relative expression of the gene (fold change). Samples were centered to one 
by normalization of the gene expression of the experimental sample to its corresponding control, in this case, WT 
(B) Western blot and quantification of SREBP1 active in CtsB and CtsL MEFs, showing a significant increase in the 
SREBP1 protein levels. (C) Quantification of western blot. For the quantification, three technical replicates and three 
biological replicates were used. WT value was centered in one, and the KO value was normalized to the WT. Graphs 
show mean ± SD; p <0.05 (*), p < 0.01 (**), p < 0.001(***); Student’s t-test; SD: standard deviation. n= 5. 
Taken together, all results obtained from the different MEFs KO are comparable to the obtained 
from the HeLa KDs cells. Mitochondrial dysfunction cells repress the cholesterol synthesis 
pathway, and lysosomal dysfunction activates the pathway.  
3.6 Cholesterol biosynthesis activity is downregulated in Ndufs4 KO mice and upregulated in 
Gaa KO mice 
To further analyze if this pattern was reproducible in vivo, not only in HeLa or MEF. We analyzed 
the expression data of the main enzymes involved in the cholesterol biosynthesis pathway in liver 




Figure 21. Transcript levels of tissue samples. Transcript levels of enzymes involved in the cholesterol biosynthesis 
pathway in 6 weeks Ndufs4 KO mice (A) and six months Gaa KO mice (B). The model of mitochondrial dysfunction 
(A) shows a decrease in the expression levels, and the opposite result was obtained in the lysosomal model (B). The 
transcript levels were determined by the ΔΔCT method using RPL7 (Ribosomal Protein L7) as a reference gene; the 
plotted value corresponds to the relative expression of the gene (fold change). Samples were centered to one by 
normalization of the gene expression of the experimental sample to its corresponding control, in this case, Ndufs4 
WT or Gaa WT respectively. Graphs present mean ± SEM; p <0.05 (*), p < 0.01 (**), p < 0.001(***); Student’s t-test; 
SEM: standard error of the mean. n= 8. 
The obtained results were comparable to the data from the different MEF cells, thus confirming 
that the regulation of the cholesterol biosynthesis could be affected by organelle dysfunction in 
liver cells. Lysosomal dysfunction triggers a small increase of 10% of transcript levels of MVK and 
PMVK that encode for enzymes of the cholesterol biosynthesis pathway (Fig. 21B). On the 
contrary, the model of mitochondrial dysfunction displays a decrease between 30-50% in 
transcript levels of the cholesterol biosynthesis pathway enzymes, but no of HMGCR (Fig. 21A). 
Once our models were validated not only in HeLa but also in MEFs and murine liver samples, we 
proceeded to identify the main mechanistic steps involved in this process. For this reason, we 
induced mitochondrial dysfunction in the lysosomal dysfunction models and vice versa. We 
achieved these aims using a pharmacological approach (detailed below). 
3.7 Pharmacological induction of mitochondrial or lysosome dysfunction 
 
3.7.1 Mitochondrial respiratory chain inhibition does not affect the enhanced activity of 
cholesterol synthesis in lysosomal defects 
Using rotenone (an inhibitor of the mitochondrial complex I), we have impaired the 
mitochondrial function in CTSB and GAA KD HeLa cells. This treatment resembles the Ndufs4 KO. 
We analyzed the expression of genes involved in the cholesterol synthesis (Fig. 22) to determine 





Figure 22. Lysosomal dysfunction model cells treated with rotenone. Cells were treated with 250 µM rotenone 
during 24h (++). Measurement of transcript levels of ACAT2, HMGCS1 and HMGCR in scrambled, CTSB KD and GAA 
KD. Lysosomal KDs showed a significant increase in the transcript levels even when they are treated with rotenone. 
The transcript levels were determined by the ΔΔCT method using RPL7 (Ribosomal Protein L7) as a reference gene; 
the plotted value corresponds to the relative expression of the gene (fold change). Samples were centered to one 
by normalization of the gene expression of the experimental sample to its corresponding control; in this case, 
scrambled (-). Graph shows mean ± SD; p <0.05 (*), p < 0.01 (**), p < 0.001(***); Student’s t-test; SD: standard 
deviation. n= 4. 
The treatment with rotenone had a different effect in each cell line. In the control cells (with 
scrambled shRNA applied), the monitored transcript levels were decreased. However, the effect 
was not consistent in the cellular models of lysosomal dysfunction were not affected by the 
treatment with rotenone. Only in CTSB KD HeLa, there was a trend to decrease the monitored 
transcript levels upon rotenone exposure. 
To clarify these results, we decided to perform a similar experiment, whereby the trafficking of 
cholesterol from the lysosome towards the ER would be inhibited in cells with mitochondrial 
dysfunction. Presumably, such experimental design may help us to elucidate which organellar 
dysfunction was predominant, the mitochondrial or lysosomal dysfunction. 
3.7.2 Treatment with U18666A increases the transcript levels of main cholesterol biosynthesis 






We measured the transcript levels of genes encoding for enzymes involved in the cholesterol 
pathway, in non-transfected HeLa cells (Fig. 23A), as well as treated with U18666A (a drug that 
blocks the transport of cholesterol from the lysosome to the ER). Transcripts were increased 
more than 5-fold in all of the genes analyzed except in phosphomevalonate kinase (PMVK).  
 
Figure 23. Pharmacological induction of cholesterol biosynthesis pathway. Measurement of transcript levels of 
main enzymes involved in the cholesterol biosynthesis. (A) HeLa cells treated during 72h and (B) Ndufs4 KO MEFs 
treated during 48h. Both graphs show a clear upregulation of the transcript levels. The transcript levels were 
determined by the ΔΔCT method using RPL7 (Ribosomal Protein L7) as a reference gene; the plotted value 
corresponds to the relative expression of the gene (fold change). Samples were centered to one by normalization of 
the gene expression of the experimental sample to its corresponding control, in this case, for (A) control and (B) 
Ndufs4 control. Graphs present mean ± SD; p <0.05 (*), p < 0.01 (**), p < 0.001(***); Student’s t-test; SD: standard 
deviation. n= 6. 
Transcript levels of our genes of interest were increased by the treatment in Ndufs4 KO MEFs 
(Fig. 23B). Here, we expected to observe a reduction in these transcript levels due to the presence 
of mitochondrial dysfunction in this cell line. However, the phenotype of the mutation was 
shielded by the effect of the drug.  
The amount of cholesterol in the cell is determined in the ER: when the cholesterol content 
decreases under 5% of total cholesterol content in the ER membrane, the lipid synthesis is 
activated (Goldstein et al., 2006). Because of this, our next step was to measure the total content 
of cholesterol in the cells using different methods. 
3.8 Cholesterol: measurement and reduction 
3.8.1 Measurement of free cholesterol content in HeLa model cells and CTS KO MEFs by filipin 
We measured unesterified (free) cellular cholesterol content using filipin. This dye has been used 




Niemann-Pick disease type C (NPC), a disease caused by defects in cholesterol efflux from 
lysosomes due to mutations of genes coding for NPC1 and NPC2 proteins (Tängemo et al., 2011). 
 
Figure 24. Measurement of free cholesterol content in HeLa KDs and CtsB and CtsL KO MEFs. A) Increase in free 
content of cholesterol in the UQCRC1 KD cells and decrease in the lysosomal dysfunction models. B) The decrease in 
free content of cholesterol in Cts KOs MEFs. In all cases, the free cholesterol content was normalized first to protein 
levels and then to their respective controls (scrambled in HeLa cells and WT in MEFs cells). Graphs show mean ± 
SEM; p <0.05 (*), p < 0.001(***); Student’s t-test; SEM: standard error of the mean. n= 10. 
In the case of UQCRC1 KD HeLa, free content of cholesterol in the cell was increased (Fig. 24A). 
On the contrary, CTSB KD and GAA KD HeLa present a significant decrease in the free content of 
cholesterol (Fig. 24A). The same result was observed in Cts KOs MEFs (Fig. 24B). These results 
may explain the differential response at the transcript level to cholesterol synthesis depending 
on which organelle is affected. 
However, since filipin is rapidly photobleached by UV light and can bind other lipids (Maxfileld 
and Wüstner, 2012), we decided to use an additional method for total cholesterol detection, 
implementing the extraction of lipids before the measurement. 
 
3.8.2 Total cholesterol content is reduced in Ndufs4 KO MEFs and not affected in lysosomal 
dysfunction 
Here, we employ a more specific method designed for cholesterol detection. The method is 
enzymatic, and it is based on the oxidation of cholesterol. The H2O2 produced in the reaction 
reacts with amplex red producing resorufin. Resorufin is highly fluorescent probe easily 





Figure 25. Measurement of cholesterol content by Amplex Red. Graphs displayin cholesterol content normalized 
to protein amount; in models of lysosomal dysfunction (A and B) and a model of mitochondrial dysfunction (C). A 
and B) Cholesterol content in CtsB, CtsL, and Gaa KO MEFs is not changed. C) Cholesterol content is reduced in 
Ndufs4 KO MEFs. Quantification indicates mean ± SEM; p <0.05 (*); Student’s t-test; SEM = standard error of the 
mean; n=4. 
Using this method, the cholesterol content of the cells was not affected in the case of CtsB, CtsL, 
and Gaa KO MEFs, although different results were obtained previously with the filipin staining. 
The Ndufs4 KO MEFs showed a decrease in the cholesterol content compared to the WT (Fig. 
25C).  
Based on the presented results, we consider the possibility that, in our model cell lines, the total 
cholesterol content remains unchanged, however, that its content in the different organelles is 
affected. Therefore, we further measured the cholesterol content in mitochondria. 
 
3.8.3 Mitochondrial cholesterol is increased in Ndufs4 KO MEFs 
In order to tackle the question defined above, we first extracted the mitochondria enriched 
fraction form Ndufs4 and Gaa KO MEFs. Next, we performed the measurement of cholesterol 




Figure 26. Measurement of mitochondrial cholesterol content by Amplex Red. Mitochondria were extracted from 
cells obtained from a cell extract fraction enriched in mitochondria. From this fraction, the cholesterol content was 
measured, and the protein concentration was determined. The cholesterol content of the mitochondrial fraction 
was significantly increased in Ndufs4 KO MEFs(A) and not changed in Gaa KO MEFs(B). Cholesterol content was 
normalized to the protein concentration of each sample. Quantification shows mean ± SEM; Student’s t-test; p <0.05 
(*); SEM = standard error of the mean; n=3  
Cholesterol content of the enriched mitochondrial fraction in Ndufs4 KO cells (Fig. 26A) displayed 
a significant increase. The opposite result was observed in total cholesterol content. However, 
there was no change in cholesterol content in Gaa KO mitochondria (Fig. 26B). 
For the next set of experiments, we aimed to remove or add cholesterol to the cells. One of the 
methods used to remove cholesterol is the treatment with cyclodextrin, the compound with the 
ability to bind cholesterol. Moreover, because cholesterol is not soluble in water, one of the most 
used forms of cholesterol delivery to the cells is using cyclodextrins as carriers. 
 
3.9 Treatment with hydroxypropyl-β-cyclodextrin (HPCD) upregulates the cholesterol 
biosynthesis in CtsB and L KO 
To achieve the aim of depleting cholesterol from the cells, we used a cyclodextrin to subtract the 
cholesterol from the cells, thus lowering the overall cellular cholesterol content. In this case, we 




Figure 27. Analysis of the transcript levels of cholesterol-related genes in CtsB and CtsL KO MEFs treated with 
HPCD. Cells were treated with 1% w/v HPCD during 4h. CtsB and CtsL KO MEFs showed an upregulation of the 
transcript level in the presence of HPDC. The transcript levels were determined by the ΔΔCT method using RPL7 
(Ribosomal Protein L7) as a reference gene; the plotted value corresponds to the relative expression of the gene 
(fold change). Samples were centered to one by normalization of the gene expression of the experimental sample 
to its corresponding control, in this case, CTS WT. Graph shows mean ± SD; p <0.05 (*), p < 0.01 (**), p < 0.001(***); 
Student’s t-test; SD: standard deviation. n= 6. 
The treatment with HPCD led to increased transcript levels of all the enzymes involved in the 
cholesterol synthesis in CtsB and CtsL KO MEFs (Fig. 27). 
 
3.10 Treatment with HPCD in Ndufs4 KO MEFs increased the transcript levels of genes from 
cholesterol biosynthesis 
Our models of mitochondrial dysfunction downregulate the expression of the enzymes involved 
in cholesterol synthesis. On the contrary, the addition of HPCD to the medium upregulates the 
cholesterol synthesis. The treatment with HPCD in the Ndufs4 KO MEFs produced a clear 
upregulation of the transcript levels (Fig. 17). The effect of the mitochondrial dysfunction in the 
cholesterol biosynthesis is suppressed by the addition of HPCD. 
Figure 28. Analysis of the transcript levels of cholesterol-related genes in Ndufs4 MEFs treated with HPCD. 
Treatment with 1% w/v HPCD during 4h. The treatment upregulates the studied genes in Ndufs4 MEFs. The transcript 
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levels were determined by the ΔΔCT method using RPL7 (Ribosomal Protein L7) as a reference gene; the plotted 
value corresponds to the relative expression of the gene (fold change). Samples were centered to one by 
normalization of the gene expression of the experimental sample to its corresponding control, in this case, Ndufs4 
WT. Graph presents mean ± SEM; p < 0.01 (**), p < 0.001(***); Student’s t-test; SEM: standard error of the mean. 
n= 6. 
In both models, cells with mitochondrial (Fig. 28) and lysosomal dysfunction (Fig. 27), the 
depletion of cholesterol from the cell triggers upregulation of the cholesterol biosynthesis 
pathway.  
One of our goals was to determinate the possible mechanism involved in our models of organelle 
dysfunction that modulates the cholesterol biosynthesis. Our hypotheses involve two central 
kinases that regulate the metabolism in the cell (Inoki et al., 2011): (i) the pathway regulated by 
mTORC complex is leading to the direct activation of SREBP1 and inhibition of lipin1; or (ii) AMPK 
regulates the pathway in an inhibitory way by phosphorylating HMGCR and ACC (acetyl CoA 
carboxylase). 
 
3.11. Determination of signaling pathways involved 
3.11.1 Blocking mTORC activity enhances the cholesterol biosynthesis pathway in CtsB KO MEFs 
To address the role of mTORC inhibition in the regulation of cholesterol biosynthesis, we treated 
CtsB KO MEFs with 250 nm Torin-1 (Fig. 18). Torin-1 is a potent inhibitor of mTORC1 and mTORC2, 
which in turn regulates the expression of SREBPs. We measured the transcript levels of genes 
encoding for the enzymes of the cholesterol biosynthesis pathway. 
These cells showed no change in the basal activity of mTORC, determined by the WB 
measurement of the phosphorylation level of ribosomal protein S6 (S6), an established target of 
mTORC1 (Fig. 29A). Under basal conditions, the relevant transcript levels in CtsB KO cells are 
increased by approximately 20 %. However, when CtsB KO cells are treated with Torin-1, the 
same transcript levels display a 2-4 fold increase (Fig. 29B). This indicates that the effect produced 
by the treatment with Torin-1 has a stronger effect on cholesterol biosynthesis than the absence 
of CtsB (Fig. 29B). 




Figure 29. Treatment with Torin increases the cholesterol biosynthesis pathway in CtsB KO MEFs. A) Left) 
representative western blot of ribosomal protein S6 (S6) and its phosphorylated form. Right) quantification. Samples 
values were normalized to CTS WT (-) which was centered in one. B) Data showing the upregulation of transcripts of 
the main genes involved in the cholesterol biosynthesis. The transcript levels were determined by the ΔΔCT method 
using HPRT (Hypoxanthine Phosphoribosyltransferase 1) as a reference gene; the plotted value corresponds to the 
relative expression of the gene (fold change). Samples were centered to one by normalization of the gene expression 
of the experimental sample to its corresponding control, in this case, CTS WT DMSO. Values are normalized to the 
WT control. Graph shows mean ± SD; p < 0.05 (*), p < 0.01(**) p < 0.001(***); Student’s t-test; SD: standard 
deviation. n= 4. 
 
3.11.2 Blocking mTORC activity does not affect the cholesterol biosynthesis pathway in Ndufs4 
KO MEFs 
The Torin 1 treatment was also applied to Ndufs4 KO MEFs (250 nM Torin 1 during 4h). In this 
system, we could not observe a significant change in the expression levels of cholesterol 
biosynthesis genes upon Torin 1 treatment, compared to the non-treated cells (Fig. 30B). A 
further change in the relevant transcript levels, detected in KO cells, is absent upon Torin 1 
treatment (Fig. 30B).  
84 
 
Measurement of the mTORC activity via the phosphorylation level of ribosomal protein S6 (S6) 
(Fig. 30A) revealed an increased mTORC activity in Ndufs4 KO MEFs. Therefore, we could have 
expected an increase in the cholesterol biosynthesis enzymes transcript levels due to mTORC 
activation. Because of that, we hypothesize that the repression of the cholesterol synthesis in 
this model of mitochondrial dysfunction is independent of the regulation of mTORC. 
 
Figure 30. Treatment with Torin does not affect the cholesterol biosynthesis pathway in Ndufs4 KO MEFs. A) Left) 
representative western blot of ribosomal protein S6 (S6) and its phosphorylated form. Right) quantification of the 
western blot. Samples values were normalized to NDUFS WT (-) which was centered in one. B) Data showing the 
downregulation of transcripts of the main genes involved in the cholesterol biosynthesis. The transcript levels were 
determined by the ΔΔCT method using RPL7 as a reference gene; the plotted value corresponds to the relative 
expression of the gene (fold change). Samples were centered to one by normalization of the gene expression of the 
experimental sample to its corresponding control, in this case, NDUFS4 WT CONTROL. Graphs present mean ± SD; p 
< 0.05 (*), p< 0.001(**) p < 0.001(***); Student’s t-test; SD: standard deviation. n= 6. 
The effect of the treatment with Torin 1 varied in each model cell line: CtsB KO cells showed an 
increase in the transcript levels of interest, but Ndufs4 KO cells were not affected even despite 
the increased activity of mTORC. Taken together, we propose that the mTORC pathway is an 
unlikely main contributor to this differential regulation of cholesterol biosynthesis. 
However, another main kinase regulates the cholesterol synthesis, AMP-activated protein kinase 
(AMPK). Its effect on the metabolic activity of cells can be divided into two main contributions: i) 
the inhibition of anabolism to minimize ATP consumption (inhibition of lipids synthesis) and ii) 
the stimulation of catabolism to stimulate ATP production (activating fatty acid oxidation) (Herzig 
and Shaw, 2018; Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 
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2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim 
et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016)(Kim et al., 2016). 
 
3.12 Upregulation of the cholesterol biosynthesis pathway in AMPK DKO MEFs  
To test the effect of mitochondrial or lysosomal dysfunction on the activity of AMPK, first, we 
obtained MEF cells from mice with knock-outs of both AMPK subunit α1 and AMPK subunit α2 
(AMPK DKO). Second, we induced a perturbation in the organelles using different drugs. We 
treated AMPK DKO cells during 24h with rotenone (inhibitor of complex I), U18666A (inhibitor of 
the cholesterol transport from the lysosome to the rest of the cell) or co-treatment. After the 
incubation period, the cells were collected for protein and RNA extraction. 
We further analyzed transcript levels of three enzymes involved in the cholesterol synthesis 
(HMGCS1, HMGCR, and MVK) (Fig. 25). It has previously been reported that AMPK represses the 
cholesterol biosynthesis. As we expected, AMPK DKO cells present an increase in the monitored 
transcript levels, compared to the WT cells.  
 
Figure 31. AMPK DKO MEFs cannot restore normal transcript levels of cholesterol biosynthesis genes under 
pharmacological co-treatment. Cells were treated with 250 nM rotenone, 10 µM U18666A, or both drugs for 24h. 
The transcript levels were determined by the ΔΔCT method using RPL7 as a reference gene; the plotted value 
corresponds to the relative expression of the gene (fold change). Samples were centered to one by normalization of 
the gene expression of the experimental sample to its corresponding control; in this case, CONTROL WT. Graphs 
show mean ± SD; p < 0.05 (*), p< 0.01(**) p < 0.001(***); Student’s t-test; SD: standard deviation. n= 6. 
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The exposure to U18666A generated a significant increase in the monitored transcript levels, in 
both the WT cells and AMPK DKO. Moreover, cells that underwent rotenone treatment display 
significantly reduced transcript levels of the HMGCS1 and HMGCR; however, MVK was not 
affected. 
The co-treatment led to an increase in the monitored transcript levels in both cell lines. WT cells 
treated with U18666A and rotenone showed a 20-50% increase in the transcript levels compared 
to WT control cells. However, in AMPK DKO cells, the expression levels of the same transcripts 
are 4-5 fold increase compared to WT control cells and three times higher than in AMPK DKO 
control. Based on these results, we showed that following the co-treatment with U18666A and 
rotenone, AMPK DKO cells are not affected in the same way as WT cells (Fig 31).  
Individual treatments with each drug reveal their opposite effects. In WT cells, the treatment 
with rotenone alone decreased the monitored transcript levels, while the same transcript levels 
are increased as a result of U18666A treatment.  
On the other hand, the treatment with rotenone led to a decrease of the monitored transcript 
levels by at least 50 % in AMPK DKO MEFs compared with WT control cells (Fig. 31). However, 
the treatment with U18666A did not additionally increase the transcript levels compared with 
the WT MEFs under the same conditions. 
 
 
Figure 32. Active SREPB1 protein levels are not affected by pharmacological treatments AMPK DKO MEFs. A) 
Western blot showing the protein levels of mature SREBP1 under the different treatments, no change was observed 
in any treatment. The quantification was done using two technical replicates. B) Quantification of the western blot, 
values were normalized to WT control cells (which was centered in one). Graph presents mean ± SD; p < 0.05 (*), p< 
0.01(**) p < 0.001(***); Student’s t-test; SD: standard deviation. n=2 
 
Although the expression of the studied genes was affected by the treatments with the applied 




could be a consequence of inactivation of AMPK, which activates the cholesterol synthesis, thus 
affecting directly the amount of active SREBP1.  
Because of these results, we consider the existence of a mechanism involved in the regulation of 
cholesterol biosynthesis that is activated when the mitochondria or the lysosome are 
dysfunctional. This could be a direct regulation (repressing the activity of enzymes involved in the 
pathway) or indirect (activating another pathway that represses the lipid synthesis) by AMPK. 
Therefore, we decided to turn to measure the AMPK activity in our lysosomal models. 
 
3.13 Measurement of AMPK activity in several models of lysosomal dysfunction 
To measure the activity of AMPK in our model cell lines, we quantified the intensity of the band 
corresponding to AMPKα Thr172 phosphorylation, which is indicative of its activity.  
In most of our lysosomal models, the activity of AMPK does not appear to be decreased (Fig. 33). 
Only Gaa KO MEFs show a significant decrease in AMPK activity. Although not significant, a 




Figure 33. AMPK activity is not decreased in all the studied models of lysosomal dysfunction. Western blot of A) 
CTSB and GAA KD HeLa, B) CtsB and CtsL KO MEFs and C) Gaa KO MEFs. Each figure corresponds to western blot 
(left) and its quantification (right). For the quantification, two technical replicates and two biological replicates were 
used. WT or scrambled value was centered in one, and the KO or KD value was normalized to the WT. Graph were 
used presents mean ± SEM; p < 0.01 (**); Student’s t-test; SEM: standard error of the mean. n=4 
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Next, we decided to repeat this experiment with a different model of lysosomal dysfunction. 
Therefore, we used cells with a knock out of lysosomal membrane glycoprotein 2 (LAMP2). This 
protein is present in lysosomal membrane and was associated to several functions, such as fusion 
of lysosomes with phagosomes(Huynh et al., 2007) and has also been proposed to serve as a 
receptor for chaperone-mediated autophagy (Bandyopadhyay et al., 2008; Cuervo and Dice, 
1996). 
Recently, LAMP2 has been associated with the binding of lipids in the lysosome, particularly 
cholesterol (Li and Pfeffer, 2016). Hence, we used Lamp2 KO MEFs as a new model cell line. 
 
3.14 Characterization of Lamp2 KO MEFs in the context of cholesterol transport 
To further test our hypothesis that cells carrying a lysosomal deficiency display upregulation of 
the cholesterol biosynthesis pathway, we measured the transcript levels of the main enzymes of 
the cholesterol biosynthesis pathway in the Lamp2 KO MEFs.  
 
Figure 34. Upregulation of transcript levels involved in the cholesterol biosynthesis pathway in Lamp2 KO MEFs. 
Increase of the expression levels of the main enzymes involved in the cholesterol biosynthesis pathway. The 
transcript levels were determined by the ΔΔCT method using RPL7 as a reference gene; the plotted value 
corresponds to the relative expression of the gene (fold change). Samples were centered to one by normalization of 
the gene expression of the experimental sample to its corresponding control, in this case, LAMP2 WT. Graph shows 
mean ± SD; p < 0.001 (***); Student’s t-test; SD: standard deviation. n=5 
The transcript levels of the enzymes of interest displayed a significant increase in Lamp2 KO MEFs 





Figure 35. Evaluation of the AMPK activity through the phosphorylation AMPKα Thr 172. AMPK activity is repressed 
in Lamp2 KO MEFs. Western blot is showing a trend to decrease (left) and its quantification (right). For the 
quantification, two technical replicates and two biological replicates were used. WT value was centered in one, and 
the KO value was normalized to the WT. Graphs show mean ± SD; SD: standard deviation. n=4 
AMPK activity tended to decrease (Fig. 35). However, there was no significant change.  
One of the essential enzymes in cholesterol synthesis is HMGCR. This enzyme is regulated in 
several ways, one of them being phosphorylation of Ser 871 (Ser 872 in humans) by AMPK. Once 
the enzyme is phosphorylated, its activity is repressed.  
 
Figure 36. Evaluation of cholesterol pathway activation by SREBP1 and pHMGCR in Lamp2 KO MEFs. The protein 
levels of SREBP1 were increased, as well as HMGCR. HMGCR was less phosphorylated in Lamp2 KO MEFs than in WT, 
suggesting activation of cholesterol pathway. For the quantification, two technical replicates and two biological 
replicates were used. WT value was centered in one, and the KO value was normalized to the WT. Western blot (left) 
and quantification (right). Graph presents mean ± SEM; p <0.05 (*); Student’s t-test; SEM: standard error of the 
mean. n=4. 
Analyzing the phosphorylation protein levels of HMGCR, we could observe a decrease. This could 
be explained due to the decreases in the activity of AMPK. A decrease in the activity correlates 
with an increase in cholesterol synthesis. Additionally, to support the hypothesis of activation of 
the cholesterol pathway, the main transcription factor of the cholesterol synthesis, SREBP1, was 
increased (Fig. 36).  
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We further aimed to compare our models of mitochondrial dysfunction (Ndufs4 KO MEFs) with 
Lamp2 KO MEFs, to investigate if the variation in the AMPK activity regulates the cholesterol 
synthesis. 
 
3.15 Comparison of AMPK activity between Ndufs4 KO MEFs and Lamp2 KO MEFs 
Comparing the AMPK activity of Lamp2 KO MEF and Ndufs4 KO MEFs (Fig. 37B), we observed a 
significant difference. The activity was decreased in Lamp2 KO MEF and increased in Ndufs4 KO 
MEFs, consistent with our expectations. The levels of active SREBP1 are not changed (Fig. 37D). 
Regarding HMGCR, Lamp2 KO cells showed a tendency to decrease its levels, but in Ndufs4 KO 
cells, no changes were observed (Fig. 37C). 
From this part of the experiments, we could propose that regulation by AMPK exists in our 
models through the inhibitory phosphorylation of HMGCR. However, further experiments need 





Figure 37. Comparison of Ndufs4 KO and Lamp2 KO MEFs in the activation of the cholesterol biosynthesis pathway. 
A) Western blot. Quantification of B) AMPK activity. For the quantification were used two technical replicates and 
three biological replicates; C) total level of HMGCR and D) levels of active SREBP1. For the quantification, two 
technical replicates and two biological replicates were used. In all the cases, the wild-type values were centered in 
one, and each KO was normalized to its WT. Graphs show mean ± SEM; p <0.05 (*); Student’s t-test; SEM: standard 





In this project, we have found that mitochondrial dysfunction and lysosomal dysfunction, both 
yield consequences on the activity of the cholesterol biosynthesis pathway, albeit of opposite 
effects. In summary, mitochondrial dysfunction represses the cholesterol biosynthesis pathway 
while lysosomal dysfunction brought to its enhanced activity. Such differential regulation of the 
cholesterol biosynthesis pathway is consistent with the phenotypes observed in these models, 
like a reduction of energy production in mitochondrial dysfunction (Suomalainen and Battersby, 
2018), and inability to degrade the macromolecules in lysosomal dysfunction (Parenti et al., 
2015). Moreover, our results strongly suggest that AMPK is a likely regulator of the cholesterol 
biosynthesis pathway. We hypostatize that HMGCR plays a key role in the mechanistic steps 
linking mitochondria and lysosomes with the cholesterol biosynthesis since it is directly regulated 
by AMPK via phosphorylation. However, additional mechanistic steps remain to be elucidated, which 
would allow us for a better understanding of the link between organellar dysfunction and cholesterol 
availability.  
 
4.1 Validation of the data obtained from NGS analysis 
4.1.1 HeLa cells 
We aimed to elucidate the mechanism(s) behind the regulation of cholesterol synthesis in the 
models of lysosomal and mitochondrial dysfunction (Fig. 12). For this reason, we generated 
models of lysosomal dysfunction (CTSB and GAA KDs) and mitochondrial dysfunction (NDUFS3 
and UQCRC1 KDs). In the case of the mitochondrial dysfunction, we only pursued the experiments 
with UQCRC1 KD since this model was extensively described by our group, describing the 
interplay between mitochondria and lysosomes (Fernandez-Mosquera et al., 2019). By taking 
advantage of available novel technologies, such as next-generation sequencing, which allows us 
to explore globally the pathways that respond to perturbations of interest, we found the 
cholesterol biosynthesis pathway to be one of the top affected pathways in the models of 
mitochondrial and lysosomal dysfunction. 
Interestingly, our analyses showed the existence of differential regulation of cholesterol 
synthesis, which displayed an organelle-specific pattern (Fig. 14). In summary, in the case of 
mitochondrial dysfunction model, a decline in the synthesis was observed. On the other hand, 
impaired lysosomal function produced an upregulation in the cholesterol synthesis pathway. 
Taken together, these results can point to the different role of cholesterol in each of the 
dysfunction models, i.e., in each of the affected organelles. In the case of mitochondrial 
dysfunction, where ATP production is reduced (Suomalainen and Battersby, 2018), it is expected 
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that most of the cellular anabolic processes (e.g., cholesterol synthesis) would be inhibited or 
attenuated due to their high energy demand (Boyle, 2005). 
The inability of cholesterol to be exported from the lysosome to the ER membrane, like in some 
lysosomal storages disorder (LSDs), might explain the increase of cholesterol synthesis in the case 
of lysosomal dysfunction. In this condition, cells would sense a decrease in the cholesterol 
content in the ER membrane, even though there is plenty of cholesterol in the lysosomes. 
We then set out to validate by qPCR the outcomes of the NGS data analyses. At the transcript 
level, in the HeLa model of mitochondrial dysfunction (UQCRC1 KD), we observed a decrease in 
the expression of genes of the cholesterol biosynthesis pathway (Fig. 15). This suggests 
repression in the cholesterol biosynthesis pathway. On the other hand, a different result was 
reported by (Kühl et al., 2017) where some of the main enzymes involved in the cholesterol 
biosynthesis, e.g., HMG-CoA synthase (HMGCS1) and farnesyl pyrophosphate synthase (FDPS), 
had a normal or slightly increased transcript levels when mtDNA gene expression is disrupted. 
However, the authors are focused on the murine heart tissue, which could be the most likely 
reason for the discrepancy between the two sets of results.  
The canonical pathway of cholesterol biosynthesis activation is regulated by SREBPs. In mammals, 
two variants of SREBPs are known: SREBP1-a and SREBP1-c. Both variants are produced from the 
same gene through the use of an alternative transcription start site. The third member of the 
family is SREBP2, encoded by a separate gene (Brown and Goldstein, 1997). SREBP1-a and SREBP2 
are the most predominant isoforms of SREBPs in cultured cell lines; SREBP2 mostly regulates the 
transcription of the genes involved in the cholesterol metabolism. However, SREBP1a strongly 
activates global lipid metabolism in rapidly growing cells (Horton et al., 2002). By evaluating the 
canonical pathway in our model of mitochondrial dysfunction, we found out that SREBP1 was 
decreased, as expected based on the reduced relevant transcript levels. These results are 
consistent with the expression data we obtained from the UQCRC1 KDs by qPCR, as wells with 
the NGS data (Fig. 17).  
In some cases, although lysosomes are able to process cholesterol for further use, the inability of 
lysosomes to degrade some macromolecules, e.g., glycosphingolipids, triggers an accumulation 
of cholesterol in lysosomes (Walkley and Vanier, 2009). This is consistent with the results 
obtained from our models of lysosomal storage disorder such as GAA KD and CTSB KD (Fig. 16), 
which presented an opposite trend compared with the mitochondrial model. In our lysosomal 
dysfunction models, the results obtained from the qPCR and the activity of SREBP1 point towards 
the activation of cholesterol biosynthesis pathway (Fig. 17).  
Despite the canonical regulator of cholesterol biosynthesis pathway being SREBP2, the 
consequences of organelle dysfunction are mostly visible at the protein levels of active SREBP1. 
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At this point, we cannot discard the possibility that an additional lipid plays an important role in 
organelle dysfunctions. Because of that, this is an essential issue to elucidate in further studies.  
In order to verify that the observed responses to organelle dysfunction were not a cell line-
specific response, limited only to HeLa cells, we employed immortalized MEFs with dysfunction 
either in mitochondria or in lysosomes (Hyman and Simons, 2011). 
4.1.2 Mouse embryonic fibroblasts and mice 
For the model of mitochondrial malfunction, we used MEFs from the Ndufs4 (core subunit of 
complex I) KO mice. The mutations in Ndufs4 subunit and its subsequent dysfunction are studied 
as a model of Leigh syndrome (Ortigoza-Escobar et al., 2016). The syndrome is a progressive 
neurodegenerative condition with highly variable symptoms, usually including hypotonia, 
dystonia, seizures, respiratory failure, and vomiting. Results obtained in this model system were 
similar to those of UQCRC1 KD in HeLa cells (Fig. 18). This suggests that the effects observed in 
HeLa cells are not limited to that model and that a similar mechanism is activated in humans and 
mice when mitochondria are compromised. Interestingly, the result also showed that 
irrespective of the perturbed complex of the respiratory chain (complex I in mice and complex III 
in humans) the impact on cholesterol synthesis was the same. Also, in this case, we could 
elucidate that the response generated by a mitochondrial malfunction in mice is SREBP1 
dependent (Fig. 18B).  
The mouse models of LSD that we evaluated in this project corresponded to knock out of three 
different lysosomal genes in MEFs: Gaa (Fig. 19A) (a model of lysosomal Pompe´s disease 
(Leborgne et al., 2017)), as well as CtsB and CtsL (Fig. 20A). Only three of these disorders can be 
classified as LSD, while the others are caused by defective cleavage of specific protein substrates 
(Ketterer et al., 2017). In all the MEF models, we obtained results similar to those that we found 
in lysosomal KDs in HeLa cells. CtsB and CtsL dysfunction could lead to a similar phenotype 
observed in Niemann Pick Type C (NPC) cells, where the cholesterol gets accumulated in the 
lysosome (Cermak et al., 2016). This could mean that a similar mechanism is employed in all these 
cases; however, the main reason for this phenotype observed in NPC cells is not well understood, 
which prevents us from exploring a similar alternative. Consistently, upregulation of most of the 
genes of the cholesterol synthesis pathway was found in these models, and this increase was 
SREBP1-dependent (Fig. 20B). Taken together, our results show that similar mechanisms regulate 
the response to cholesterol biosynthesis in HeLa cells and MEFs. These mechanisms are 
independent of the enzyme that is inhibited. 
The expression levels of the studied genes for the cholesterol synthesis in mouse liver, the most 
important organ for the de novo synthesis of lipids (Nguyen et al., 2008), followed the same trend 
observed in the MEF cells (Fig. 21). However, the regulation of the cholesterol pathway in the 
liver is not only dependent on SREBPs, but can also partially rely on nuclear receptors such as 
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liver X receptors (LXRs). These receptors are nuclear proteins that play central roles in the 
transcriptional control of lipid metabolism; once activated, they induce the synthesis of an array 
of genes involved in the cholesterol absorption, efflux, transport, and excretion (Zelcer, 2006). 
Even though we obtained similar results in liver and our models of organelle dysfunction, we 
cannot conclude that the regulation of the pathway in the tissue is that same as in cells. Further 
experiments need to be done to clarify if LXRs are critical for the observed regulation in tissue. 
4.1.3 Effect of lysosomal dysfunction in a model of mitochondrial dysfunction and vice versa 
Administration of rotenone to cells produces inhibition of the mitochondrial complex I. The effect 
of complex I inhibition can be observed in the decrease in oxygen consumption (Fernández-
Mosquera et al., 2017). Besides, it leads to a decrease in the transcript levels of the enzymes 
involved in cholesterol synthesis (Fig. 22). However, the same treatment does not trigger the 
decrease in the same transcript levels in CTSB and GAA KD HeLa (Fig. 22 CTSB and GAA). This 
result suggests that the effect of the lysosomal dysfunction triggers a mechanism of cholesterol 
synthesis upregulation that suppresses the effect produced by the mitochondrial dysfunction. 
On the other hand, when cells with mitochondrial dysfunction are treated with an inhibitor of 
cholesterol export from the lysosomes, such as U18666A (Eid et al., 2017), the relevant transcript 
levels are not restored to those observed in control conditions (Fig. 23B). From these results, we 
can conclude that the effect of the lysosomal dysfunction in the cholesterol pathway has a 
stronger effect than the one of mitochondrial dysfunction. 
The observed results can be explained by analyzing the possible mechanisms in which the cell is 
able to obtain cholesterol. Lysosomes are essential for the processing of cholesterol absorbed 
during endocytosis, while mitochondria are organelles important for the production of Acetyl-
CoA, a precursor of most of the lipid molecules. However, Acetyl-CoA can also be produced in 
the cytoplasm. In the mitochondrial dysfunction model, the cells would not be able to produce 
the same amount of cholesterol due to a decrease in the production of Acetyl-CoA (Lozoya et al., 
2019), but they could use the cholesterol absorbed through endocytosis. If the lysosomes are 
dysfunctional, the absorption of cholesterol would be hampered, thus triggering an evident 
upregulation of the cholesterol synthesis pathway. 
4.2 Cholesterol: measurement and reduction 
4.2.1 Measurement of cholesterol content 
We then evaluated the cellular cholesterol content to verify how it was impacted by the changes 
in the regulation of cholesterol synthesis. For this purpose, we employed the Filipin stain, which 
binds to free cholesterol (Fig. 24). 
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As we expected, the free content of cholesterol was increased in our models of mitochondrial 
malfunction and decreased in the case of the lysosomal dysfunction. The ER is the place where 
the cholesterol levels in the cell are sensed. When the content of cholesterol is lower than 5%, 
the cholesterol synthesis pathway is activated to restore the cholesterol levels (Brown et al., 
2002). So, in the case of the mitochondrial dysfunction, downregulation of the cholesterol 
pathway is consistent with a higher content of cholesterol in the cell (Fig. 24A). Conversely, the 
reduced cellular cholesterol content in lysosomal dysfunction models is consistent with the 
increase in cholesterol biosynthesis (Fig. 24A and B). 
The upregulation of the cholesterol biosynthesis pathway in the models of lysosomal malfunction 
could be explained by the inhibition of cholesterol transport out of the lysosomes. Then, the 
cholesterol cannot be transported to the ER membrane, and the cells sense its low content 
(Vance and Karten, 2014). This will, in turn, induce the de novo synthesis, although the lysosomes 
are full of cholesterol that cannot leave this organelle (Kristiana et al., 2008). In this context, the 
total content of cholesterol increases due to de novo synthesis and the inability of the cell to use 
cholesterol storage in the lysosomes. 
The free cholesterol measurement by Filipin has several important practical considerations. 
Filipin is rapidly photobleached by the UV light intensity available in most fluorescence 
microplate readers (Vanier and Latour, 2015), it can cause deformation in the membrane altering 
the interaction membrane:protein (Steer et al., 1984), and it can label other lipids such as GM1 
ganglioside (Maxfileld and Wüstner, 2012). Due to these concerns, we decided to use a 
biochemical assay, where the lipids are extracted from the cell, to evaluate total cholesterol 
content. The lipids are mixed with a cholesterol oxidase enzyme-producing hydrogen peroxide 
(H2O2). The H2O2 reacts with a probe forming a new compound that can be easily detected by 
measuring its fluoresce (Infante and Radhakrishnan, 2017). 
Interestingly, the results obtained using this technique were different from those obtained using 
Filipin. Models of lysosomal dysfunction did not show any change in the cholesterol content (Fig. 
25A and B). Nevertheless, the model of mitochondrial dysfunction showed the opposite result, a 
significant reduction of the cholesterol content (Fig. 25C). The difference in the results could be 
explained by the ability of Filipin to bind only the unesterified cholesterol (Vanier and Latour, 
2015), while the kit allows us also to measure cholesterol esters. 
In conditions of some LSDs, e.g., Niemann Pick Type C, it has been reported that there is an 
increase of the cholesterol levels in the mitochondrial membrane (Charman et al., 2010). For this 
reason, we decided to measure the cholesterol content also in mitochondria. Gaa KO MEFs show 
no change (Fig. 26B), but Ndufs4 KO MEFs, there is a significant increase in the mitochondrial 
cholesterol content. It has been reported that an increase of cholesterol content in the 
mitochondrial membrane could induce the decrease in the glutathione levels, which results in 
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increased ROS levels, further triggering apoptosis (García-Ruiz et al., 2016). Additionally, changes 
in the cholesterol content of the mitochondrial membrane influence the mechanism of 
membrane permeabilization, also leading to apoptosis (Bosch et al., 2011).  
4.2.2 Cholesterol extraction with hydroxypropyl-β-cyclodextrin (HPCD) 
Using cyclodextrins, cyclic oligosaccharides consisting of multiple glucopyranose water-soluble 
units along with a hydrophobic pocket, we have performed cholesterol extraction (Zidovetzki and 
Levitan, 2007). The hydrophobic pocket is the cholesterol-binding site. For example, 
supplementing medium with 5-10 mM β-cyclodextrin for more than two hours removes 80-90% 
of cellular cholesterol (Yancey et al., 1996). For this reason, we used a milder cyclodextrin, 2-
Hydroxypropyl-β-cyclodextrin (HPCD) (Shen et al., 2014). 
The addition of HPCD into the medium produced an increase in the transcript levels of the main 
enzymes involved in the cholesterol biosynthesis in both models of organelle dysfunction. 
Interestingly, HPCD was able to rescue the effect of the mitochondrial dysfunction on the 
cholesterol biosynthesis pathway (Fig. 28); sequestration of cholesterol from the cell appears to 
reactivate the cholesterol biosynthesis despite the mitochondrial dysfunction. The group of 
Brown (Abi-Mosleh et al., 2009) demonstrated that the treatment with HPCD could rescue the 
accumulation of cholesterol in the lysosomes observed in NPC1/2 KO human fibroblast. HPCD 
releases the cholesterol from the lysosomes after which a portion of the released cholesterol can 
be transferred to ER for esterification. CtsB and CtsL KO MEFs showed the opposite result (Fig. 
27): the transcript levels were increased, suggesting an activation of the cholesterol pathway. 
This experimental difference leads to the conclusion that even if an accumulation of cholesterol 
is present in CTSB/CTSL deficient cells, the mechanism involved should be different from the NPC 
cells. 
4.3 Determination of signaling pathways involved 
4.3.1 Lipid pathway biosynthesis induced by mTORC 
mTORC has an essential function as nutrient/energy/stress sensor. It can induce the lipogenesis 
in hepatocytes by directly activating SREBPs (Eid et al., 2017). In cells, mTORC1 promotes SREBPs 
translocation from the ER to Golgi, where SREBPs are cleaved and activated (Peterson et al., 
2011). However, it is unclear whether and how mTORC1 influences ER cholesterol to regulate 
SREBPs (Eid et al., 2017). 
For the inhibition of the mTORC pathway, we used TORIN1, an inhibitor of mTORC1 and mTORC2 
(Thoreen et al., 2009). MEF cells exposed to TORIN1 show a different response to the effect of 
the drug. CtsB KO MEFs (Fig. 29B) increased considerably the transcript levels of the enzymes 
from cholesterol synthesis; on the other hand, there was no change in their transcript levels in 
Ndufs4 KO MEFs (Fig. 30B). Ndufs4 KO mice, studied as a model of Leigh Syndrome (mitochondrial 
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disease), show signs of symptoms alleviation upon the treatment with rapamycin (an inhibitor or 
mTORC) (Cherezov et al., 2013). As expected in our Ndufs4 KO MEFs, an increase in the activity 
of mTORC was observed (Fig. 30A). Despite the increase of mTORC activity, which would lead to 
an increase in the cholesterol synthesis, in Ndufs4 KO MEF, the synthesis of cholesterol is 
repressed. This result suggests that the functional complex I, and likely functional mitochondria, 
are essential to activate cholesterol synthesis and underscores the importance of mitochondrial 
function in cholesterol metabolism. In summary, the inhibition of mTORC seems not to affect the 
cholesterol pathway in Ndufs4 KO MEFs. 
CTSB regulates lysosomal dynamics. When the enzyme is not present due to a knock out or is 
pharmacologically inhibited, the activity of mTORC is reduced, resulting in overt activation of 
TFEB (Man and Kanneganti, 2016). Despite the reduction in the activity of mTORC, when the 
activity of CTSB is blocked, we could not observe a reduced activity of mTORC in normal 
conditions (Fig. 29A). In CtsB KO MEFs, the inhibition of mTORC increased the transcript levels of 
the main enzymes involved in the cholesterol biosynthesis to the extent higher than in normal 
conditions. The predicted result based on the previous experiment would have been a reduction 
in the cholesterol biosynthesis; however, in this case, an opposite result was observed. For this 
reason, we contemplate the possibility that a different regulator of the pathway is responsible 
for the increase or decrease of the cholesterol biosynthesis in either mitochondrial or lysosomal 
dysfunction.  
4.3.2 Lipid pathway biosynthesis repressed by AMPK 
The first pathway ever that was identified as a target of AMPK was the lipid and sterol pathway. 
AMPK inhibits these pathways through inhibitory phosphorylation of the acetyl-CoA carboxylases 
ACC1 and ACC2, which catalyze the first step of de novo lipid synthesis, and HMGCR (Carling et 
al., 1987; Munday et al., 1988).  
To identify the role of AMPK in our models of organelle dysfunction, we took advantage of AMPK 
double KO MEFs, MEF cells lacking the AMPK catalytic subunit α1 and α2. Cells were treated with 
rotenone and U18666A. Consistent with our expectations, cells lacking AMPK activity in normal 
conditions showed an increase in the of HMGCS1, HMGCR and MVK transcript levels (Fig. 31 
Control) and an increase of active SREBP1 protein levels (Fig. 31). The inactivity of AMPK triggers 
the cholesterol biosynthesis due to the inhibitory role of AMPK in the lipid synthesis. 
The treatment with rotenone (Fig. 31 Rotenone) reproduces the results obtained in our models 
of mitochondrial dysfunction (Fig. 15 and Fig. 18A). Addition of U18666A increased the relevant 
transcript levels (Fig. 31 U18666A) in the same way as lysosomal dysfunction. These results 




Nonetheless, the co-treatment (U18666A and Rotenone, Fig. 31) showed a different trend: WT 
cells showed an increase in the transcript levels of HMGCS1, HMGCR, and MVK compared with 
the control WT. The effect of U18666A treatment could not be reverted in any of the KO cell 
lines. The levels of SREBP1 are not affected by any drug treatment (Fig. 32). This would suggest 
an essential role of AMPK in the studied mechanism since in the conditions where we could have 
expected a restoration of the transcript levels to basal values, co-treatment, the cells were not 
able to restore the normal regulation of cholesterol synthesis in the absence of AMPK. This 
significant result gave us a hint that AMPK could be essential to explain the differential regulation 
of the cholesterol pathway in our models of lysosomal and mitochondrial dysfunction.  
4.3.3 Regulation of HMGCR 
To test the hypothesis that differential regulation of AMPK is essential for the differential 
regulation of the cholesterol synthesis, we decided to measure the AMPK activity in our models. 
The AMPK activity in CTSB KD HeLa (Fig. 33A), CtsB and CtsL KO MEFs (Fig. 33B) were not changed. 
Nevertheless, it was previously reported that inhibition of CTSB produced an increase in the 
AMPK activity (Man and Kanneganti, 2016). GAA KD HeLa (Fig. 33A) showed no significant 
increase in AMPK activity, but a significant decrease was observed in Gaa KO MEF.  
Due to this difference in the AMPK activity between our models of lysosomal dysfunction, we 
decided to use another model of LSD - Danon disease. The origin of this LSD is associated with a 
glycogen storage disease due to LAMP2 deficiency (Onyenwoke and Brenman, 2015) and the 
phenotype is characterized by severe cardiomyopathy and skeletal muscle weakness (Lieberman 
et al., 2012). LAMP2 has been associated with cholesterol stability and transport itself (Li and 
Pfeffer, 2016). The transcript levels of the cholesterol pathway in Lamp2 KO MEFs were 
significantly increased (Fig. 34), and the protein levels of SREBP1 were increased as well (Fig. 37). 
Most of the lysosomal dysfunction models used in this study were deletions of hydrolytic 
enzymes, e.g., CTSB and GAA. However, in the case of LAMP2, the protein is a constitutive 
membrane protein of the lysosome, and the result obtained was consistent with the previously 
described models: an increase in the main transcript levels of the enzymes involved in the 
cholesterol biosynthesis and an increase of the protein levels of SREBP1.  
In our study, there was a trend to decrease AMPK activity in Lamp2 KO MEFs (Fig. 36). One 
possible way to inhibit the cholesterol pathway by AMPK is the phosphorylation of HMGCR on 
Ser871 (Munday et al., 1988). As we expected, the phosphorylation levels of HMGCR were 
decreased (Fig. 36), supporting our hypothesis of the role of AMPK in the studied mechanism. 
To further validate our hypothesis, we measured the AMPK activity in the model of mitochondrial 
dysfunction, Ndufs4 KO MEFs (Fig. 37B). There was a trend towards increasing the AMPK activity 
in MEF cells. However, these results are different from those previously reported by our group, 
where AMPK activity was reduced in brain homogenates of Ndufs4 KO mice (Fernandez-
101 
 
Mosquera et al., 2019). This might be due to the high importance that the cholesterol has for the 
brain metabolism and since the blood-brain barrier prevents the entry of cholesterol-rich 
lipoproteins all cholesterol must be made locally (Björkhem and Meaney, 2004). Cholesterol brain 
metabolism is separated from the rest of the body (Martin et al., 2014). 
In the interest of time, we were not able to keep working on our hypothesis concerning the role 
of AMPK in our models or discover any other signaling pathway affected. Further experiments 




5. SUMMARY AND CONCLUSIONS 
Nowadays, there are several studies done in the field of mitochondrial diseases and lysosomal 
storage diseases and how these organelle dysfunctions affect the organism, triggering several 
disorders and pathologies according to the affected tissue. However, how and why these diseases 
affect the lipid synthesis is not well defined. Therefore, this project was based on understanding 
the main mechanism involved in cholesterol synthesis. 
This thesis describes the effect that mitochondrial dysfunction models (cell lines deficient in 
UQCRC1 and NDUFS4 (Model of Leigh Syndrome)), and lysosomal storage diseases, (deficiency 
of lysosomal hydrolases GAA, CTSB, and CTSL or glycoprotein of the membrane, e.g., LAMP2) 
yield on cholesterol biosynthesis. Taking advantage of the next-generation sequencing, we could 
observe a differential regulation of the cholesterol pathway between the two organelle 
dysfunctions. We not only validated the data obtained from NGS, analyzing the transcript levels 
of the main enzymes involved in the cholesterol pathway but also extended the findings to 
different models and cell types. Additionally, we reported the importance of the regulation of 
the pathway by SREBP1 in our models. Despite changes in the activity of SREBP1, according to 
the studied models of organelle dysfunction, we reported a change of free cholesterol levels, 
even though the total amount of cholesterol was not altered (except in Ndufs4 KO MEF). To 
understand the change in the cholesterol content and the activation/inhibition of SREBP1, we 
evaluated the role of the two main kinases involved in cellular metabolism, mTORC, and AMPK. 
The results obtained from the inhibition of mTORC do not explain the changes reported in our 
models. On the other hand, AMPK activity trend to be increased in the mitochondrial models and 
decreased in our lysosomal models could explain the changes in the cholesterol biosynthesis 
pathway through the regulatory phosphorylation of HMGCR. 
As the conclusion of this thesis project, we could report the possible role of AMPK in the 
differential regulation of the cholesterol pathway in the models of mitochondria and lysosomal 
dysfunction. However, further experiments need to be done to finally elucidate and explain the 
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